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Summary	
Both	diabetes	and	depression	are	enormous	health	problems.	Several	chronic	 illnesses	are	co‐
morbid	with	depression,	and	diabetes	 is	not	an	exception.	Scientists	and	epidemiologists	have	
long	 been	 conducting	 research	 on	 the	 relationship	 between	 diabetes	 and	 depression.	 Several	
epidemiological	studies	confirm	this	relationship.	
	
Aim	
The	 aim	 of	 this	 project	 was	 to	 investigate	 this	 relationship	 between	 concurrent	 use	 of	
antidepressants	and	antidiabetic	in	users	of	different	numbers	of	antidepressants	and	different	
regimens	of	diabetes	treatment.		
	
Methodology	
The	study	is	a	cross‐sectional	design;	Data	on	prescribed	and	dispensed	medication	from	2006	
obtained	from	all	pharmacies	across	Norway,	supplied	by	the	Norwegian	Prescription	database	
are	 the	 source	 of	 material	 in	 this	 study.	 	 The	 database	 was	 pseudonymized	 upon	 reception.	
Therefore,	data	cannot	integrally	be	traced	back	to	any	individual.	There	was	therefore	no	need	
to	involve	the	Regional	or	Local	Committee	for	Medical	Research	Ethics	nor	the	Norwegian	Data	
Inspectorate	since	 the	database	 is	properly	secured.	However,	permission	 to	use	 the	data	was	
obligatory.	
Individuals	 between	 20	 and	 79	 years	 of	 age	 are	 the	 subjects	 selected	 from	 the	 database	 and	
categorized	 into	users	of	 insulin	only,	 those	who	received	oral	anti‐glycaemia	agents	only	and	
those	 who	 received	 both	 insulin	 and	 oral	 anti‐glycaemia	 agents.	 Individuals	 were	 further	
categorized	according	to;	whether	received	single	type,	multiple	types	or	no	antidepressants.			
Odds	ratio	was	then	calculated	and	adjusted	for	age	and	gender	using	binary	logistic	regression.	
	
Results	
The	 odds	 ratio	 of	 using	 single	 antidepressants	were	 1.5	 times	 higher	 among	 individuals	who	
received	 insulin	 only	 and	 individuals	who	 received	 oral	 anti	 glycaemic	 only	 compared	 to	 the	
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general	population	(OR	=1.55,	95%	CI:		1.49‐1.62	and	OR=1.56,	95%	CI:		1.52‐1.60	respectively).	
Individuals	who	received	both	insulin	and	oral	anti	glycaemic	agents	had	twice	the	risk	of	using	
single	antidepressants	compared	to	the	general	population;	(OR=2.0,	95%	CI:		1.90‐2.11).		
	
In	 the	 usage	 of	 multiple	 antidepressants,	 users	 of	 insulin	 only	 had	 also	 1.5	 times	 the	 risk	
compared	to	the	general	population	(OR=1.52,	95%	CI:	1.38‐1.66).	Users	of	oral	anti	glycaemic	
agents	only	had	1.8	times	the	risk	compared	to	the	general	population	(OR=1.84.	95%	CI:		1.74‐
1.94).	The	risk	was	significantly	higher	than	the	risk	of	single	antidepressants	usage	and	shows	
that	multiple	antidepressants	usage	is	more	common	among	these	individuals	compared	to	the	
general	population.	The	risk	was	also	higher	among	individuals	who	received	both	insulin	and	
oral	glycaemic	agents	(OR=2.25,	95%	CI:	2.04‐2.50)	compared	to	the	general	population.	
	
Within	age	groups;	among	users	of	insulin	only,	individuals	of	age	group	50‐59	had	the	highest	
risk	 (OR=1.78,	 95%	 CI:	 1.62‐1.95)	 of	 using	 single	 antidepressants	 compared	 to	 the	 general	
population.	Among	users	of	oral	anti	glycaemic	only,	age	groups	30‐59	had	the	highest	risk	(1.8‐
2.4	times)	compared	to	the	general	population.		The	odds	ratio	for	individuals	who	received	both	
insulin	 and	oral	 anti	 glycaemic	 agents	was	 also	 higher	 among	 age	 groups	20‐59	 (2‐4.5	 times)	
compared	to	the	general	population.	The	risk	for	individuals	who	received	both	insulin	and	oral	
anti	glycaemic	agents	was	higher	than	the	risks	 for	users	of	 insulin	only	and	users	of	oral	anti	
glycaemic	agents	only.		
The	 risk	 of	 using	 multiple	 antidepressant	 among	 users	 of	 insulin	 only	 was	 higher	 (2	 times)	
among	age	groups	20‐39	compared	 to	 the	general	population.	 	Among	 individuals	of	oral	 anti	
glycaemic	 only,	 age	 groups	 20‐59	 had	 higher	 significant	 risks	 (2‐3	 times)	 in	 using	 multiple	
antidepressants	 compared	 to	 the	 general	 population.	Whiles	 among	 users	 of	 both	 insulin	 and	
oral	 anti	 glycaemic	 agents,	 individuals	 of	 age	 groups	30‐59	had	 the	 highest	 risk	 (3‐4.5	 times)	
compared	to	the	general	population.	
Regarding	gender,	 the	risk	of	using	multiple	antidepressants	was	higher	 than	the	risk	 in	using	
single	 antidepressants.	 Although	 the	 prevalence	 is	 higher	 in	 women	 than	 men,	 there	 is	 a	
negligible	difference	in	the	risk	of	using	antidepressants	among	men	than	women.																
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Conclusion	
The	usage	of	single	antidepressants	was	higher	 than	multiple	antidepressants	among	diabetes	
individuals	 as	 it	was	 for	 the	general	population.	 For	 individuals	using	oral	 antidiabetic	 agents	
only,	 the	 risk	of	using	multiple	antidepressants	versus	single	antidepressants	was	higher	 than	
for	 the	 general	 population.	 The	 reason	 for	 this	 needs	 further	 study.	 Although,	 there	 are	
limitations	of	cross‐sectional	studies	and	secondly,	there	was	no	means	to	adjust	for	factors	as	
BMI,	 CHD,	 smoking	 and	physical	 activities,	 the	 result	 confirms	previous	 studies	 suggesting	 an	
association	between	diabetes	and	depression.		
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1 Introduction	
 
1.1 Diabetes	Mellitus;	an	Overview	
Normally,	 the	 blood	 glucose	 level	 is	 strictly	 regulated	 by	 insulin,	 a	 hormone	 produced	 by	 the	
pancreas.		The	action	of	insulin	is	to	reduce	the	blood	glucose	level.	When	the	blood	glucose	level	
elevates	 (for	 example,	 after	 meals),	 insulin	 is	 released	 from	 the	 pancreas	 into	 the	 blood	 to	
normalize	 the	 glucose	 level.	 The	 absence	 of	 normal	 insulin	 production	 in	 diabetes	 causes	
hyperglycemia.	Hyperglycemia	is	a	condition	that	results	because	cells	of	the	body	are	unable	to	
take	up	and	use	glucose.	Diabetes	is	a	serious	medical	condition	meaning	even	though	it	can	be	
controlled	it	cannot	be	axed	off	and	lasts	for	a	lifetime.		
The	term	diabetes	mellitus	is	a	metabolic	disorder	of	various	etiologies,	characterized	by	chronic	
hyperglycemia	 with	 irregular	 carbohydrate,	 fat	 and	 protein	 metabolism.	 These	 irregularities	
result	from	defects	in	insulin	secretion	and	insulin	action	or	a	combination	of	both[1].		
Diabetes	 mellitus	 symptoms	 include	 unusual	 thirst	 and	 hunger,	 blurred	 vision,	 recurring	 of	
infections,	 delays	 in	 healing	 (cuts	 or	 bruises),	 frequent	 urination	 and	weight	 loss.	 In	 its	most	
serious	 situation,	 there	 could	 be	 development	 of	 ketoacidosis,	 which	 may	 in	 turn	 lead	 to	
drowsiness	or	coma.	If	unfortunate	or	without	reasonable	treatment,	the	condition	may	lead	to	
the	unexpected;	death[1,	2].	Long‐term	effect	of	the	disease	without	significant	intervention	may	
lead	to	damage,	dysfunction	and	failure	of	various	organs.	
	
1.2 Prevalence	of	diabetes	
The	prevalence	of	type	2	diabetes	in	Norway	is	increasing	at	a	higher	rate.	The	global	prevalence	
of	type	2	diabetes	is	also	at	a	remarkably	higher	rate,	whiles	the	prevalence	of	type	1	diabetes	is	
at	 a	moderate	 ascension	 [3‐6].	 The	 prevalence	 	will	 continue	 to	 grow	 (within	 all	 age	 groups)	
from	2.8%	in	2000	to	about	4.4%	in	coming	years	(2030)	[3].	Logically	the	study	estimates	the	
number	of	known	diabetes	 to	be	doubled	by	 the	year	2030.	 	 It	was	 in	 turn	estimated	 that	 the	
total	number	of	individuals	having	the	disease	will	rise	from	171	million	in	2000	to	366	million	
in	2030.	Women	outnumber	men	 in	 the	disease,	 even	 though	 the	prevalence	 is	higher	 in	men	
than	women.		
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The	estimate	 for	diabetes	 (285	million)	 in	2009/2010	 is	 scary	and	 the	mortality	 associated	 is	
about	3.9	million	 [7].	The	number	of	prevalence	 is	 approaching	 the	366	million	 that	was	 first	
estimated	to	be	in	2030.	The	latest	estimate	is	490	million	by	2030	and	the	cost	associated	with	
diabetes	 expenditure	 is	 minimally	 about	 200‐300	 billion	 US	 dollars	 [7].	 The	 principal	
contributing	 factor	 to	 the	 rise	 of	 the	 prevalence	 of	 the	 disease	 is	 from	 older	 people	 in	 the	
population,	 specifically	 45‐64	 years	 in	 developing	 countries	 and	 65	 years	 and	 above	 in	
developed	countries[3,	6,	7].	However,	obesity	is	also	a	significant	factor	[3,	8].	Even	if,	obesity	is	
not	counted,	the	prevalence	will	still	be	higher	[3].	Zimmet	et.al	has	unfolded	some	explanation	
to	this	cause;	as	the	behavior	and	changes	of	human	lifestyle	may	have	aided	the	rapid	increase	
in	the	incidence	of	diabetes	worldwide	[8].	
In	 Norway	 alone,	 the	 estimation	 of	 people	 	with	 diabetes	 (per	 2004)	 	 is	 between	 90000	 and	
120000	[4].	It	was	in	turn	estimated	that	the	number	of	diagnosed	patients	could	be	the	same	as	
the	number	of	undiagnosed	[4].	Logically	there	are	a	lot	of	people	living	with	the	disease	without	
knowing	it.	In	another	study	with	different	methodology	it	was	also	estimated	that	the	number	
of	people	 treated	 for	diabetes	 in	Norway	was	 	110	000	[9],	 this	 is	 in	accord	with	 the	previous	
studies	 mentioned	 above.	 The	 incidence	 rate	 for	 type	 1	 diabetes	 was	 higher	 than	 expected	
among	children	below	15	years	of	age	[9],	despite	previous	research	estimations	as	stable	[10].	
Norway	is	among	countries	with	the	highest	rate	of	incidence	in	regard	to	diabetes	type	1,	and	
the	 prevalence	 of	 diabetes	 type	 2	 has	 also	 been	 increasing	 [5,	 11,	 12],	 and	 the	 latest	 figures	
indicate	that	the	prevalence	will	continue	to	grow,	especially	among	men	[8].	In	Norway	the	total	
expenses	 on	 diabetes	 is	 about	 to	 €535	 million,	 making	 about	 2.6%	 of	 the	 total	 health	 care	
expenditure[13].	
	 	
1.3 The	β‐cell	
Knowledge	of	the	anatomical	parts,	physiological	and	pharmacological	processes	gives	a	better	
understanding	 of	 the	 diseases.	 It	 is	 essential	 to	 understand	 the	 structure	 of	 the	 β‐cells	which	
serves	as	understanding	tool	to	the	functions	of	these	complex	micro‐organs,	and	finally	gives	a	
better	knowledge	about	the	disease.	
The	 β‐cells	 are	 located	 in	 the	 tiny	 cell	 clusters	 (of	 the	 islets	 of	 Langerhans)	 in	 the	 human	
pancreas.	They	are	 the	body’s	 source	of	 the	essential	hormone	 insulin.	The	β‐cells	outnumber	
other	cells	in	the	pancreas.	They	constitute	about	60‐80	percent	in	the	islets	of	Langerhans	[2,	
14‐16]	(Fig.1a).	The	β‐cells	also	release	C‐peptide;	a	polypeptide	fragment	produced	during	the	
cleavage	of	proinsulin	 in	 the	production	of	 insulin	[17‐19].	C‐peptide	produced	with	 insulin	 in	
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equimolar	quantities	 [20‐22]	helps	 to	prevent	neuropathy	 (a	CNS	disease)	 and	other	vascular	
diseases	 of	 diabetes	 [23,	 24].	 The	β‐cell	mass	 can	 also	 be	 estimated	 	 by	measuring	plasma	C‐
peptide	levels	[20].		
The	 β‐cells	 in	 response	 to	 glucose	 stimulus	 can	 produce	 amylin	 (also	 known	 as	 IAPP	 islet	
amyloid	 polypeptide).	 Amylin	 is	 a	 37‐amino	 acid	 polypeptide	 hormone	 that	 is	 simultaneously	
secreted	with	insulin.	[17,	25,	26].	Amylin	is	a	pancreatic	endocrine	hormone	and	contributes	to	
glycemic	 control.	 Amylin	 can	 to	 some	 extent	 inhibit	 some	 nutrient	 (especially	 glucose)	 in	 the	
plasma.	It	acts	synergistically	to	insulin.	This	means	insulin	regulates	long	term	food	intake	and	
amylin	decreases	short‐term.	
	
	
Fig.1a Islets	of	Langerhans	(from	pancreas).	
	
1.3.1 Insulin	
Insulin	is	a	hormone	of	two	peptide	chain,	α	and	β	subunits	connected	by	disulphide	linkages	of	
21	and	30	amino	acid	residues	respectively[2,	16,	17].	Preproinsulin	is	first	synthesized	(in	the	
rough	endoplasmic	reticulum)	and	then	transported	to	the	Golgi	apparatus.	There,	it	undergoes	
a	proteolytic	cleavage	to	proinsulin	and	then	 further	cleavage	 into	 insulin	and	C‐peptide.	Both	
hormones	are	then	stored	in	the	granules	of	the	β‐cells	and	released	in	equimolar	quantities	(by	
exocytosis)	when	needed.	The	main	factor	regulating	the	synthesis	and	secretion	of	insulin	is	the	
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blood	 glucose	 concentration	 level.	 Insulin	 metabolism	 occurs	 in	 the	 liver	 and	 kidneys	 (by	
disulphide	cleavage)	and	has	a	half‐life	of	about	5–8	min.[16,	27].		
																																																																																																																																														 																																																																										
1.3.2 The	secretion	mechanism	of	insulin	
There	is	always	a	response	to	any	change	in	blood	glucose	level	[17,	28,	29].	The	response	occurs	
in	 two	phases	(Fig.1b).	An	 immediate	response	 that	release	 the	hormone	 from	the	store	room	
and	a	slower	or	delayed	release	to	support	an	ongoing	insulin	action	or	the	continuation	of	new	
synthesis	 [17,	 30].	 The	 mechanisms	 of	 these	 two	 phases	 differ	 in	 terms	 of	 inner	 membrane	
proteins.	 Syntaxin	 protein	 family	 are	 also	 involved	 in	 the	 first	 phasic	 releases	 of	 insulin	 [31]	
(Fig.1c).	This	response	is	to	some	extent	unusual	in	diabetes	mellitus	[17].	The	release	of	insulin	
involve	Ca2+	 ions	 and	 secretion	 from	vesicle[30].	 The	ATP‐K	 channel	 regulates	 the	membrane	
potential	in	the	β‐cells.		
The	 process	 starts	when	 glucose	 first	 enters	 the	 β‐cells	 via	 a	membrane	 transporter	 (Glut‐2)	
after	 having	 been	 through	 a	 series	 of	metabolism	 by	 the	 enzyme	 glucokinase	 (a	 rate	 limiting	
enzyme)[17]	(Fig.1d).	Then	 followed	by	glycolysis	(glycolytic	generation	of	pyruvate)	 [17,	32].	
The	activity	of	lactate	dehydrogenase	and Lactate	transport	activity	of	plasma	membrane	(in	the	
β‐cell)	 	 play	 an	 important	 role	 in	 determining	 the	 concentration	 of	 	 extracellular	ATP[33‐35].		
Increase	of	extracellular	ADP	leads	to	increased	concentration	of	intracellular	ATP.	This	results	
in	 blockade	 of	 the	 potassium‐ATP	 channels	 and	 ultimately	 leads	 to	membrane	 depolarization	
[17,	36].	Depolarization	opens	 the	voltage	Ca2+	channels	and	hence	 influx	of	Ca2+	 [17,	37].	The	
end	result	is	an	elevation	of	cytoplasmic	Ca2+	concentration.	Together	with	the	aid	of	amplifying	
messengers	(including	di‐acyl‐glycerol,	non‐esterified	arachidonic	acids)	leads	to	the	release	of	
insulin	 secretion	 [17,	 30].	 The	 process	 of	 secretion	 continues	 in	 loop,	 increasing	 glucose	
transporters	and	opening	several	glucose	gates	[28].	The	loop	breaks	when	glucose	is	no	longer	
needed.	
	
	
	
	
                                                         Introduction 
 
5 
 
																				 	
Fig.1b Immediate	response	in	phase	one	is	where	insulin	is	highly	released	in	normal	individuals.	In	
phase	2,	both	normal	and	type	2	are	good,	whiles	type	1	is	seriously	hampered.		
									
	
																								 	
Fig.1c The	secretion	process	involves	syntaxin	proteins	in	phase	1,	but	not	in	phase	2.	
												
                                                         Introduction 
 
6 
 
																 	
Fig.1d Ilustration	of	the	secretion	process	of	nsuin	
	
	
1.3.3 Regulation	of	Insulin	
As	 stated	 earlier,	 the	 regulation	 of	 insulin	 secretion	 strictly	 depends	 on	 the	 plasma	 glucose	
concentration.	The	 control	of	 insulin	 secretion	 from	 the	β‐cells	 and	 the	biological	 and	 cellular	
effects	 on	 target	 tissues	 are	 extremely	 vital	 to	 the	 homeostasis	 of	 glucose.	 The	 pancreas	 can	
sensor	 increase	 in	plasma	 glucose	 concentration	 (example	 after	 a	meal)	 and	 stimulate	 insulin	
secretion,	whereas	a	decrease	inhibits	secretion.	
Amino	acids	(mainly	arginine	and	leucine)	can	also	regulate	insulin	secretions	[17].	Alanine	and	
glutamine	 can	 also	 regulate	 the	 β‐cell	 function	 and	 insulin	 secretion	 [38,	 39].	 Fatty	 acids,	 the	
parasympathetic	 nervous	 system,	 peptide	 hormones,	 and	 substances	 that	 can	 stimulate	 the	
sulfonylurea	receptors	all	have	the	ability	to	increase	insulin	secretion	(illustration	in	Fig.1e).	
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Fig.1e Regulation	of	Insulin	
	
The	glucose	concentration	in	the	blood	is	also	regulated	by	adrenalin,	sympathetic	nerve	fibers	
of	the	liver	and	other	fatty	tissues.	Adrenalin	and	noradrenalin,	amylin,	somatostatin	all	inhibit	
insulin	secretion,	thereby	increasing	the	blood	glucose	level[17].	
	
1.3.4 Functions	of	Insulin	
Insulin	have	 some	 critical	 functions	 and	 are	normally	 or	 very	often	divided	 into	 (i)	metabolic	
effects	in	regard	to	carbohydrate,	lipid,	and	protein	synthesis,	and	(ii)	growth	and	developments	
effects	on	DNA	synthesis,	cell	division	and	proliferation.	
The	metabolic	effects	of	insulin	are	usually	targeted	on	muscle	cells	of	both	cardiac	and	skeletal,	
fatty	cells	 in	 the	adipocytes	 (yielding	glycerol	 for	 triglyceride	synthesis),	and	 the	 liver	cells.	 In	
the	 liver	 and	 other	 tissues,	 insulin	 increases	 glucose	metabolism	 by	 inhibiting	 glycogenolysis	
and	 gluconeogenesis	 at	 the	 same	 time	 stimulating	 glycogen	 synthesis.	 Insulin	 transport	 is	
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extremely	 slow	 in	 the	muscle.	 Insulin	 promotes	 glucose	 transport	 in	 the	muscle	 through	 the	
glucose	transporter	(Glut‐4)	to	increase	glycogen	synthesis	and	glycolysis	[17,	27,	28].		
Insulin	promotes	also	protein	synthesis	by	enhancing	absorbent	of	amino	acids	into	the	muscle.	
It	 retards	 protein	 catabolism	 and	 increase	 the	 availability	 of	 amino	 acids	 in	 the	 liver.	 Insulin	
enhances	the	conversion	of	excess	glucose	into	fatty	acids	(as	triglycerides).	The	fatty	acids	are	
in	a	form	of	very	low‐density	lipoproteins	[17,	27].	
Insulin	receptors	are	found	in	the	nerve	cells	of	the	brain.	Although	insulin	can	be	transported	
across	the	blood	brain	barrier,	it	has	little	or	no	effect	on	the	human	brain.	 	The	brain	cells	are	
permeable	to	glucose	and	are	therefore,	independent	of	insulin.		
	
	
1.3.5 Action	mechanisms	of	insulin	
The	 insulin	 receptor	 is	 a	 hetero	 tetramer	 consisting	 of	 two	 extracellular	 α‐subunits	 and	 two	
trans‐membranous	β‐subunits	held	 together	by	disulfide	 linkages	 (Fig.1f).	The	 two	α‐subunits	
(binding	sites)	are	extracellular	of	the	cell	membrane	whiles	the	two	β‐subunits	(kinase	family)	
are	intracellular	of	the	cell	membrane.	
Insulin	binds	to	a	receptor	seat	(α	site)	on	the	surface	of	its	target	cells.	The	binding	stimulates	
the	 kinase	 receptor	 (β‐unit),	 resulting	 in	 auto‐phosphorylation	 of	 the	 receptor	 on	 tyrosine	
residues	using	ATP	as	phosphate	donor	 [17,	40].	 Insulin	can	stimulate	 the	kinase	receptors	 to	
increase	 the	response	rate	 rather	 than	changing	substrate	affinity.	The	mechanism	 is	not	 fully	
understood,	but	there	is	inhibitory	effects	from	the	α‐unit	on	the	β‐units	[40].	
Once	 the	 β‐subunits	 are	 auto	 phosphorylated,	 they	 act	 as	 tyrosine	 kinases	 receptors	 that	
phosphorylate	insulin	receptor	substrate‐1	(IRS‐1).	Intracellular	proteins	(phosphatidylinositol	
3‐kinase)	containing	SH‐bonds	are	then	phosphorylated	by	IRS‐1.	The	interaction	generates	cell	
signal	response	that	travels	further	to	other	cells.	This	interaction	has	several	significant	effects,	
including	the	mobilization	of	the	insulin	responsive	glucose	transporters	(Glut‐4)	from	the	Golgi	
apparatus	to	the	plasma	membrane	in	both		muscle	and	fat	cells	[17,	27].	
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Fig.1f Illustration	of	action	mechanisms	of	insulin	
	
1.4 Glucose	control	in	the	brain	
Primarily,	the	energy	source	of	the	brain	is	glucose.	Insulin	has	remarkably	little	or	no	effect	on	
glucose	uptake	 in	the	brain.	The	brain	 is	permeable	to	glucose	(through	glucose	transporters).	
The	brain	can	utilize	glucose	without	the	intervention	of	insulin.		It	is	particularly	important	to	
keep	the	blood	glucose	level	as	normal	as	possible	such	that	the	brain	does	not	enter	into	shock.	
The	 glucose	 transporters	 are	 Glut‐1	 and	 Glut‐3	 and	 are	 stereospecific	 to	 D‐glucose.	 The	
regulation	of	the	transporters	is	active	during	brain	development	(Fig.1g).	
Research	has	proven	that	Glut‐1	develops	at	birth	and	grows	rapidly	into	maturity	after	10‐20	
days.	 Glut‐1	 exists	 in	 two	 isoforms	 having	 different	 molecular	 weights	 and	 is	 unevenly	
distributed	 on	 the	 luminal	 and	 or	 abluminal	 membranes.	 It	 is	 profoundly	 present	 in	 the	
endothelial	cells	(both	arterioles	and	venules),	capillaries	and	astrocytes	in	the	brain.	Scientific	
studies	have	proven	that	Glut‐1	is	the	primary	transporter	regulating	glucose	transport	into	the	
brain	[41‐43].	
                                                         Introduction 
 
10 
 
Defects	in	Glut‐1	transporter	across	the	blood	brain	barrier	could	cause	Glut‐1	disease	syndrome	
in	infants.	A	syndrome	characterized	by	seizures,	delayed	maturation	and	other	diseases[43].		
Glut‐3	matures	together	with	the	maturation	of	the	blood	brain	barrier	(BBB).	It	fully	develops	
normally	 between	 21‐30	 days.	 It	 is	 located	mostly	 in	 the	 neurons,	 and	 hence	 is	 the	 neuronal	
transporter	in	the	brain.	
The	glucose	transport	is	passive	in	the	brain	and	requires	no	energy	input.	Therefore,	a	steady‐
state	 transport	 is	 always	 maintained	 by	 glucose	 equilibrium.	 Intracellular	 enzymatic	
contribution	is	also	needed	in	the	transport	processes.	Glucose	transport	depends	somehow	on	
the	availability	of	both	Glut‐1	and	Glut‐3.	The	density	of	Glut‐3	 increases	during	hypoglycemia	
while	 that	 of	 Glut‐1	 remains	 unchanged.	 This	 means	 hypoglycemia	 stimulates	 more	 Glut‐3	
transporters	and	hyperglycemia	are	partly	due	to	down	regulation	of	Glut‐1[41,	42].		
Astrocytes	 assist	 in	 the	 uptake	 of	 glutamate	 (excitatory	 agent	 in	 the	 brain).	 Stimulation	 of	
glutamate	transporters	indirectly	increases	glucose	uptake[44].	
.		
	 	
Fig.1g Glucose	transporters	in	the	brain	
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1.5 Types	of	diabetes	mellitus	
The	 four	 types	of	diabetes	are	diabetes	 type	1,	diabetes	 type	2,	other	specifics	and	gestational	
diabetes.	The	first	 three	are	according	to	etiological	cause.	The	etiological	 types	determine	the	
characteristics	associated	with	diabetes	mellitus	[1].			
"Other	 specific"	 diabetes	 is	 less	 common	 and	 is	 usually	 caused	 by	 drug,	 toxic	 or	 chemical	
induced	 infections,	 diseases,	 immune	 mediated	 diabetes	 and	 genetic	 defects,	 (that	 could	 be	
associated	with	diabetes).		
Gestational	 Diabetes	 occurs	 under	 pregnancy,	 usually	 as	 a	 temporary	 condition.	 	 It	 usually	
affects	about	2‐4	%	of	pregnancies	and	could	also	increase	the	risk	of	diabetes	especially	in	older	
women.	 The	 etiological	 causes	 include	 carbohydrate	 and	 glucose	 intolerance	 resulting	 in	
hyperglycemia	and	insulin	resistance	(during	pregnancy)	[1,	45‐48].	
Most	cases	of	diabetes	are	diabetes	 type	1	and	 type	2.	They	have	 less	 in	common,	but	a	 lot	of	
differences.	The	main	difference	can	also	be	seen	in	Fig.1b.	
	
1.5.1 Type	1	diabetes		
Type	 1	 diabetes	 results	 from	 the	 body's	 inability	 to	 produce	 insulin.	 Insulin	 should	 be	
administered	by	other	means	(example	by	syringe).	
Damage	to	the	β‐cells	in	the	pancreas	or	serious	diseases	that	can	inhibit	insulin	production	or	
secretion	can	 lead	to	type	1	diabetes	[2,	28,	49,	50].	 In	many	patients	virus	 infections	or	auto‐
immune	diseases	may	cause	the	destruction	of	β‐cells	[2,	17,	50,	51].	
Auto‐immune	diseases	in	type	1	diabetes	occur	as	a	complex	product,	resulted	from	an	immune	
response	precipitated	by	an	attacked	from	the	immune	system	on	the	proteins	of	β‐cells.	These	
immune	responses	are	autoantibodies	that	prevent	or	inhibit	the	β‐cell	production	of	insulin.	In	
the	long	run,	there	could	be	destruction	of	β‐cells	[50,	52],	.	
Other	 factors	 like	 insulin	 resistance[17,	 50],	 and	 or	 genetic	 heritability[17,	 53‐55]	 may	 also	
influence	the	clinical	condition	of	the	disease.	In	many		cases,	hereditary	is	strictly	involved	[2].	
Environmental	factors	or	social	conditions	(including	dietary	supplements,	age,	race,	education,	
marital	 status,	 health	 control,	 prenatal	 care	 or	 virus	 infections	 could	 also	 lead	 directly	 or	
indirectly	to	the	potentiation	of	the	disease)	[56,	57].	The	MIDIA	project	in	Norway		conducted	
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research	 on	 environmental	 factors,	 and	 concluded	 that	 virus	 infections	 or	 diet	 can	 also	 cause	
type	1	diabetes	in	children	with	known	genetic	risks	[58].	
1.5.2 Treatment	of	type	1	diabetes	
Treating	 diabetes	 is	 to	 keep	 the	 blood	 sugar	 (glucose)	 as	 normal	 as	 possible	 and	 ameliorate	
quality	of	life.	Maintaining	the	average	blood	glucose	level	help	reduce	the	risk	of	both	micro	and	
macro	vascular	disease,	reduce	symptoms	and	reduce	mortality	[59‐61].		
Type	1	diabetes	is	usually	treated	with	insulin.	Insulin	cannot	be	administered	orally	because	it	
is	labile	to	gastric	juices	in	the	stomach	(PH5).	The	treatment	of	type	1	diabetes	is	by	injecting	
insulin	 subcutaneously,	 where	 it	 enters	 the	 blood	 stream	 and	 become	 available	 for	 the	 cells.	
There	are	many	preparations	of	insulin,	and	these	include	soluble	insulin	for	rapid‐	short	acting	
insulin	 effects,	 partially	 soluble	 and	 insoluble	 insulin	 preparations	 for	 intermediate	 and	 long‐
acting	 insulin	 respectively[17,	 60].	 Some	 patients	 may	 need	 preparations	 of	 short	 and	 long	
acting	of	 insulin,	which	are	suitable	throughout	the	day	and	or	night	prescribed	by	the	doctor.	
Treatment	 of	 Glucose	 control	 alone	 does	 not	 necessarily	 reduce	 the	 risk	 of	 complications	 in	
diabetes.	 The	 risk	 complications	 can	 also	 be	 reduced	 by	 combining	 with	 dietary	 adjustment,	
exercise	and	appropriate	self‐monitored	of	blood	glucose	[59,	61].	
	
1.5.3 Type	2	diabetes		
Type	II	diabetes	is	a	medical	disorder	of	both	insulin	resistance	and	abnormal	insulin	secretion	
[17,	28]	which	ultimately	results	in	increased	plasma	insulin	concentration.	Several	factors	are	
responsible	for	the	cause	of	type	2	diabetes	and	insulin	resistance	is	one	of	them.		
Insulin	resistance	 is	a	response	from	the	β	cells,	because	the	metabolic	effects	of	 insulin	could	
not	be	properly	handled	by	target	tissues.	 Insulin	resistance	disturbs	or	 interrupts	the	storage	
and	usage	of	carbohydrate	metabolism.	This	affects	blood	glucose	 level.	Excess	glucocorticoids	
(Cushing’s	 syndrome	 or	 steroid	 therapy),	 excess	 growth	 hormone	 (pregnancy,	 gestational	
diabetes,	ovary	diseases),	auto	antibodies	to	the	insulin	receptor	mutations	of	insulin	receptor,	
genetic	 obesity,	 hemochromatosis	 (a	 hereditary	 disease	 that	 causes	 tissue	 iron‐accumulation)	
are	all	factors	that	can	cause	insulin	resistance	[2].		
Metabolic	syndrome	comprises	of	factors	that	cause	insulin	resistance.	The	metabolic	syndrome	
sometimes	called	 insulin	 resistance	syndrome	 [60,	62,	63],	 	 (due	 to	symptoms	similarity),	 is	a	
combination	of	medical	disorders	(metabolic	risk	factors)	that	can	increase	the	risk	of	diabetes	
(typically	 diabetes	 type	 2)	 and	 cardiovascular	 disease	 [62,	 63].	 The	 risk	 factors	 include	
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overweight	or	obesity,	physical	 inactivity,	and	genetic	 factors	 [64].	The	mechanism	underlying	
insulin	resistance	and	metabolic	risk	factors	and	or	insulin	resistance	and	obesity	are	not	quite	
understood	 [2,	 64].	 Other	 factors	 include	 accumulation	 of	 abdominal	 fat	 (abdominal	 obesity),	
fasting	hyperglycemia,	lipid	abnormalities	such	as	increased	blood	triglycerides	(and	decreased	
of	the	bloods	high‐density	lipoprotein‐cholesterol),	hypertension	or	related	diseases	and	insulin	
resistance	with	or	without	glucose	intolerance	[2,	62,	64‐66].	Genetic	syndromes,	 increasing	of	
age	and	environmental	factors	are	typically	associated	with	insulin	resistance	and	diabetes	type	
2	[2,	66‐69].	Diet	lifestyle	can	be	a	serious	problem	and	cause	of	diabetes	type	2	[2,	65,	69].	
	
1.5.4 	Treatment	of	type	2	diabetes		
Untreated	diabetes	leads	to	metabolic	disorders	(ketoacidosis)	and	complications	(micro	and	or	
macro	vascular	complications).	Treating	Type	2	diabetes	is	usually	done	in	a	systematic	manner	
because	glucose	control	alone	 (as	a	mono	 therapy)	may	not	be	sufficient	 to	 reduce	 the	risk	of	
macro‐vascular	 in	 diabetes	 [60].	 As	 stated	 under	 SD5	 in	 the	 global	 diabetes	 guidelines,	
individuals	diagnosed	with	diabetes	should	be	offered	with	appropriate	treatment	and	care[70].	
This	 is	 a	 remarkably	 strong	 and	 powerful	 statement	 made	 in	 the	 guidelines.	 	 Appropriate	
treatment	 and	 care	 is	 strictly	 necessary	 and	 aims	 or	 will	 aim	 to	 reduce	 glycaemia,	 blood	
pressure,	and	perhaps	factors	characterized	by	metabolic	syndrome.	Monitoring	complications,	
modifications	 of	 dietary	 and	 exercise,	 medications,	 appropriate	 self‐monitored	 blood	 glucose	
(SMBG)	may	all	be	a	beneficial	treatment	and	care	[17,	60,	61,	71].		
Education	 is	 part	 of	 the	 recommendations	 used	 in	 the	 treatment	 of	 diabetes	 type	 2.	 Newly	
diagnosed	diabetes	patients	can	be	helped	to	 initiate	effective	self‐care	through	education	[59,	
71,	72].	Self‐	management	education	(with	glucose	monitoring	devices,	exercise	and	nutrition)	
could	prevent	acute	complications	and	reduce	 the	risk	of	 long‐term	complications.[59,	71‐74].	
Educational	recommendations	involving	any	health	personnel	or	health	departments	could	help	
elaborate	 the	 risks	 in	 foot,	 skin,	 and	 dental	 care,	 smoking	 and	 if	 possible	 preconception	 care,	
pregnancy,	and	gestational[75,	76].	
Diet	therapy	(diet	regulation)	for	non‐insulin	dependent	diabetes	is	necessary	because	obesity	is	
also	 a	 risk	 factor	 of	 insulin	 resistance	 and	 β‐cell	 defect.	 Lifestyle	 interventions	 are	 essential	
aspects	of	the	management	of	diabetes	(example	fiber‐rich	food,	reduction	of	fat	intake)	[72,	77].	
Weight	 reduction,	 exercise	 and	 or	 oral	 medication,	 can	 help	 control	 glycaemic	 [1,	 61,	 70].	
Physical	activity	has	proven	to	be	effective	in	reducing	obesity	and	risks	in	diabetes	type	2[70,	
71,	78,	79].	Physical	activity	in	general	improves	blood	flow	and	blood	pressure[74,	80].	
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1.5.5 	Oral	anti	glycaemic	agents	
Oral	glucose‐lowering	drugs	are	first	recommended	if	lifestyle	interventions	(nutrition,	exercise	
etc.)	alone	is	unable	to	maintain	normal	blood	glucose	control	level	[61,	70,	74,	79].		
Glycemic	control	can	cause	micro‐vascular	risks	and	conventional	risk	factors	(dyslipidemia	and	
hypertension)	cause	macro‐vascular	risks.	So	drug	treatments	are	to	reduce	these	risks.	There	is	
variety	 of	 oral	 anti	 hyperglycemic	 agents	 available.	 These	 agents	 differ	 in	 their	 efficacy	 for	
reducing	HbA1c,	FPG,	and	PPG,	 side	effects	 such	as	weight	gain,	bone	 fracture,	and	congestive	
heart	 failure.	 	 They	 are	 carefully	 and	 systematically	 chosen	 (to	 suit	 individuals)	 and	 used	 as	
mono	therapy	or	in	combination	as	a	target	to	control	blood	glucose	level.		
Biguanides	reduce	hepatic	glucose	production	by	exceedingly	complex	mechanisms	that	are	not	
well	understood.	They	reduce	hepatic	glucose	metabolism	(and	possibly	 in	the	 intestines[61]),	
increase	 absorption	 of	 glucose	 by	 the	 peripheral	 tissues	 and	 skeletal	 muscle	 [17,	 61,	 81].	
Metformin	is	the	only	drug	in	this	class,	very	widely	used	globally	as	first‐line	treatment	because		
it	is	favorable	for	both	morbidity	and	mortality[82].	Metformin	has	its	side	effect	as	well	and	is	
dose	related.		Among	its	side	effects	are	gastrointestinal	discomfort,	lactic	acidosis	(an	extremely	
rare	 disorder)[17].	 	 Patients	with	 renal	 or	 hepatic	 diseases	 are	 not	 recommended	 to	 use	 this	
drug.	
Sulfonylureas	synthesized	 from	sulfonic	acid	and	urea	was	 first	developed	 in	 the	1950's.	They	
act	directly	on	the	β‐cells	to	stimulate	insulin	secretion	[17]	provided	there	are	some	β‐cells	left	
[61].	 Their	 mechanism	 of	 action	 is	 on	 the	 potassium	 channel,	 where	 they	 cause	 membrane	
depolarization	by	causing	an	influx	of	Ca2+	ions.	Sulfonylureas	are	well	tolerated	but	could	have	
extremely	severe	adverts	effect	 like	hypoglycemia	(which	could	 last	 longer)	although	modified	
newer	 drugs	 reduce	 these	 risks.	 Another	 unfortunate	 side	 effect	 is	 the	weight	 gain,	 and	 they	
interact	 with	 some	 key	 antibiotics	 [17,	 61,	 83].	 Glipizide,	 glimepirid	 and	 glibenclamide	 are	
among	the	drugs	in	this	group.	
Thiazolidinediones	 reduce	 glucose	 resistance	 in	 the	 muscles,	 fat	 and	 liver	 cells	 by	 the	 act	 of	
increasing	 their	 sensitivity	 to	 insulin,	 although	 they	 have	 extremely	 slow	 onset	 after	
commencing	treatment.	Thiazolidinediones	are	ligands	to	the	peroxisome	proliferator‐activated	
receptor	gamma	(PPAR‐gamma),	which	is	most	highly	available	in	adipocytes,	muscle	and	liver.	
Among	its	side	effects	are	weight	gain,	edema,	anemia,	pulmonary	edema	and	congestive	heart	
failure	[17,	61,	83,	84]. Pioglitazone	and	rosiglitazone	are	among	the	drugs	 in	this	group.	Only	
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pioglitazone	 is	available	 in	Norway.	Rosiglitazone	 is	not	registered	 in	Norway	(unregistered	 in	
2010	due	to	its	increase	of	cardiovascular	risks).	
Alfa‐Glucosidase	 Inhibitors	 act	 by	 delaying	 the	 metabolism	 and	 absorption	 of	 carbohydrates.	
This	helps	to	reduce	the	total	production	of	glucose	level	after	meals.	This	means	they	inhibit	the	
rate	of	digestion	in	the	proximal	small	intestines.	They	are	useful	in	treating	patients	where	the	
disease	 is	 inadequately	controlled	by	diet.	Acarbose	(Precose)	and	miglitol	(Glyset)	are	among	
the	 members	 in	 this	 group.	 Only	 acarbose	 is	 registered	 in	 Norway.	 Adverts	 effect	 includes	
diarrhea	[17,	61,	83,	84].	
Dipeptidylpeptidase‐4	(DPP‐4)‐inhibitors	are	another	drugs	being	actively	used	 these	days	 for	
treatment	 of	 steroid‐induced	 diabetes.	 They	 improve	 glucose	metabolism	 and,	 in	 some	 cases,	
they	 outperform	 metformin	 when	 it	 comes	 to	 dosage	 increasing	 and	 side	 effects.	 DPP‐4	
inhibitors	prevent	 the	 inactivation	of	 glucagon‐like	peptide	1	 (GLP‐1),	which	 is	 responsible	 in	
increasing	 levels	 of	 active	 GLP‐1.	 They	 have	 in	 common	 with	 thiazolidinediones	 in	 that	 they	
increase	insulin	secretion	and	sensitivity.	DPP‐4	also	reduces	glucagon	secretion,	meaning	it	can	
reduce	blood	glucose	 level	 [61,	85,	 86].	 In	Norway,	 sitagliptin,	 vildagliptin	 and	 saxagliptin	 are	
among	the	registered	drugs	in	this	group.	
Combination	 Therapy;	 there	 are	 combination	 drugs	 of	 the	 agents	 mentioned	 above.	 DPP‐4	
inhibitors	 are	often	 combined	with	metformin.	 In	Norway,	 the	 registered	among	 this	 group	 is	
Metformin	and	pioglitazone.	
	
1.5.6 Management	and	prevention	of	diabetes	
The	maintenance	of	type	2	diabetes	is	similar	to	that	of	diabetes	type	1.	In	Norway,	the	main	aim	
is	to	achieve	symptom	free,	good	quality	life	and	normal	life	durability	and	ultimately	to	reduce	
atherosclerosis	diseases	[61,	87].	
In	this	new	era,	based	on	a	variety	of	researches,	there	have	now	been	introduced	good	models	
and	measures	for	prevention	this	disease.		Researches	have	unfolded	resources	into	disposal	for	
preventive	and	control	of	diabetes	mellitus.	Good	breastfeeding	practices[88],	early	detection	of	
gene	types	(that	can	cause		the	disease),	identification	of	other	cytokines	and	HLA	genotypes	in	
the	early	stages[53,	54],	and	or	environmental	factors[56]	can	also	assist	in	preventing	diabetes,	
since	 these	 factors	 have	 been	 proved	 to	 be	 involved	 in	 diabetes[89‐91].	 Although	 some	
researches	 did	 	 not	 find	 strong	 significant	 correlation	 between	 diabetes	 type	 1	 and	 HLA	
genotypes	nor	birth	weight	[92],	it	is	still	worth	to	consider	these	factors.	
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In	Norway,	there	are	good	therapeutic	guidelines	for	the	prevention,	diagnosis	and	treatment	of	
diabetes	 available	 for	 health	 workers	 [73],	 and	 among	 others	 researches	 recommending	
procedures	for	prevention	[93]	and	not	the	least,	hospitals	and	primary	health		procedures	and	
guidelines.	
Some	diabetes	patients	 are	 reluctant	 to	 exercise.	This	 could	be	a	 lack	of	understanding	of	 the	
disease.	 	Motivation,	educational	recommendations,	encouragement,	and	follow‐up	could	be	an	
asset	to	health	care	professionals	that	could	perhaps	better	the	situation.		
Most	of	 the	guidelines	used	 in	 the	management	of	diabetes	are	mentioned	under	 treatment	of	
type	2	diabetes	above.	
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1.6 Depression	
Depression	has	become	a	global	problem,	and	major	depression	is	currently	leading	globally,	in	
the	cause	of	disability,	and	has	become	a	serious	public	health	problem[94,	95].  
Depression	is	a	serious	medical	illness	that	involves	the	brain.	Depression	is	a	medical	condition	
or	illness	involving	various	physiological,	affective	and	cognitive	manifestations.	Depression	may	
differ	 from	 milder	 symptoms	 to	 more	 severe	 forms,	 including	 symptoms	 like	 delusional	
thoughts,	 somatic	 concerns	 and	 to	 the	worse	 extent,	 suicidal	 ideas	 over	 long	 periods	 of	 time.		
WPA	have	 defined	 the	 term	depression	 (from	medical	 	 view)	 in	 three	 different	meanings;	 i)a	
mood,	a	feeling,	an	emotion,	an	affective	state	ii)	an	indication	of	a	depressive	disorder;	and		iii)	
the	depressive	disorder	itself	[96].		
The	 symptoms	of	depression	 include	both	emotional	 (example	 low	morale,	 less	or	no	 reason)	
and	 biological	 symptoms	 (moral	 retardation	 of	 either	 thought,	 activity	 or	 both	 and	 sleep	
disorders,	appetite	disturbances)[97,	98]	
There	are	two	different	types	of	depression,	namely	unipolar	and	bipolar.	Unipolar	disorder	is	
more	 frequently	 observed	 and	 is	 usually	 associated	 with	 the	 stressful	 way	 of	 life	 events.	
Depression	usually	could	be	morbid	with	anxiety	and	agitation.	 	Bipolar	comes	earlier	 in	adult	
life	and	involves	fluctuation	of	disposition	over	a	period.	It	is	usually	accompanied	with	mania.	
	 	
1.6.1 Etiology	and	prevalence	of	depression	
The	causes	are	not	 fully	known.	A	combination	of	biological,	genetic,	and	physiological	 factors	
are	among	the	causes.	Research	on	homozygote	has	revealed	that	genetics	could	be	a	cause	[94,	
99,	100].		Additional	factors,	perhaps	sociological	factors	(like	stressful	environment)	and	other	
psychosocial	factors	could	cause	of	the	disease[94,	96].		
The	WHO,	 	 Harvard	University	 and	 the	World	Bank	 jointly	 reported	 depression	 as	 the	 fourth	
cause	of	disease	burden	and	accounts	for	3.7%	of	total	disability‐adjusted	life‐years	(DALYs)	in	
1990	 [95].	After	a	decade,	depression	 is	 still	 the	 fourth	 cause	of	disease	burden	and	 this	 time	
accounting	 for	 4.4%	 of	 total	 DALYs[95,	 97].	 Depression	 poses	 the	 largest	 number	 of	 nonfatal	
burden,	with	magnitude	of	circa	12%	of	all	 total	years	 lived	with	disability	worldwide	[95,	97,	
101].	
Risk	of	developing	depression	 is	about	10‐20%	in	 females	whiles	 the	number	 is	 less	 in	males.	
Individuals	under	45	years	are	 likely	 to	be	victimized	than	 individuals	above	45	years	 [94].	 In	
general,	 depression	 affects	 both	males	 and	 females	 and	 is	 common	 in	 females	 than	males[97,	
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102].	 An	 independent	 	 study	 projected	 the	 burden	 of	 depression	 to	 be	 50%	 higher	 among	
females	than	males[103].	According	to	the	WHO	report,	poverty,	sex,	age,	conflict	and	disasters,	
physical	 diseases,	 and	 family	 and	 social	 conditions	 	 are	 among	 factors	 accounting	 for	 the	
prevalence	of	depression[97].		
In	Norway,	depression	affects	about	8	%	of	the	population	and	costs	the	state	(or	tax	payers)	a	
sum	of	about	1.5	billion	NOK	per	annum.	Though	depression	affects	the	patient	and	community,	
the	disease	is	still	preventive	(through	psychological	and	cognitive	methods)[104].	
	
1.6.2 Theories	of	depression	
Depression	can	devitalize	human	life	severely.	Scientists	are	aware	of	the	impact	of	depression	
and	long	been	studying	this	illness.	There	are	several	theories	of	depression.	The	monoamine	
theory	is	one	of	the	oldest	theories.	Research	has	enable	scientist	to	propose	other	theories.		
	
1.6.3 The	monoamine	theory	
Earlier	 studies	 focused	on	catecholamine	system	specifically	noradrenalin	as	a	potential	 cause	
for	depression.	Further	research	extended	the	theory	to	include	the	serotonin	system	as	a	cause	
for	 depression.	 Research	 has	 now	 extended	 the	 use	 of	 drugs	 that	 interact	 with	 monoamine	
uptake	 or	 reuptake	 and	 enzymatic	 metabolism	 for	 the	 treatment	 of	 depression.	 Schildkraut	
proposed	 the	monoamine	 theory	 five	decades	ago[105].	 It	 states	 that	depression	 is	a	 result	of	
decrease	of	 the	monoamines;	noradrenaline,	dopamine	and	especially	5‐HT	at	a	special	 site	 in	
the	brain	[106‐110].	Mania	occurs	from	overactivity	of	the	neurotransmitters	in	the	brain.	
This	means	that	depression	could	be	restore	to	normal	by	administering	antidepressants	agents.	
These	agents	increase	synaptic	concentrations	of	monoamines	(particularly	catecholamine	and	
or	serotonin)	in	the	brain	through	various	mechanisms.	The	mechanisms	of	actions	occur	in	the	
mesolimbic	pathway	of	the	brain.	
Series	of	 studies	have	proved	 that	 there	 is	ample	evidence	supporting	 the	monoamine	 theory.	
The	 supporting	 evidence	 from	 the	 studies	 includes	 the	 inhibition	 of	 NA,	 5‐HT	 reuptake	
(improves	 mood),	 inhibition	 of	 MAO	 (yields	 antidepressant	 effect),	 and	 lastly	 reserpine	
(depletes	 monoamine	 storage	 causing	 depression).	 MHPG	 is	 the	 main	 metabolite	 of	
noradrenaline	 and	 5‐HIAA	 is	 the	 metabolite	 of	 serotonin.	 	 These	 metabolites	 appear	 in	 the	
cerebrospinal	fluid	in	the	brain,	blood	and	urine.	Some	studies	have	proved	that	urinary	MHPG	
levels	are	either	high	or	low	in	depressed	patients	compared	to	normal	individual[98,	111,	112].	
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Other	 evidence	 supporting	 the	 theory	 is	 that	 agents	 that	 block	 the	 synthesis	 of	 serotonin	 or	
noradrenaline	are	able	to	antagonize	the	therapeutic	effects	of	antidepressants.		
Evidence	 suggests	 that	 dopamine	 transmission	 is	 low	 in	 depression	 and,	 agents	 that	 increase	
dopaminergic	transmissions		are		effective	antidepressants[98].		
There	are	of	course	problems	with	theories	or	hypothesis,	and	the	monoamine	theory	is	not	an	
exception.	There	are	some	missing	links	(antidepressants	unable	to	onset	an	immediate	effect).	
Antidepressants	 block	 monoamines	 reuptake	 immediately	 on	 administration,	 but	 the	 clinical	
effects	are	not	observed	until	2	weeks	or	longer.	[106,	113‐116].	Scientists	have	tried	to	explain	
the	delay	as	due	to	series	of	reaction	from	receptor	to	gene	transcription	before	results	can	be	
seen[108,	116]	 and	 that	may	 involve	neurons	 and	 synaptic	 activities[117].	Many	 studies	have	
put	 the	 theory	 to	 tests	 through	 urine	 or	 blood	 samples	 for	 irregularities	 of	 biochemical	 in	
depressed	 or	 manic	 patients.	 Some	 studies	 tested	 receptors,	 enzymes,	 transporters	 and	
metabolites	 of	 the	monoamines.	Most	 of	 the	 tests	 gave	 negative	 results[98].	 It	 still	 remains	 a	
question	why	both	cocaine	and	amphetamine	have	the	ability	to	enhance	the	monoamine	levels	
in	the	brain	and	still	lack	the	antidepressant	effects.	
The	bottom	line	is	that	the	older	version	of	the	monoamine	theory	is	now	modified	or	expanded	
to	 include	 abnormalities	 of	 second	messenger	 receptors,	 gene	 expressions	 and	 the	 release	 of	
neurotransmitters	 from	 the	 same	neurons	 that	 contain	or	harbors	 the	neurotransmitters.	The	
monoamine	hypothesis	cannot	be	rejected	and	still	dominates	the	basics	or	form	the	baseline	in	
the	research	field	of	antidepressant.	Lastly	it	provides	a	firm	ground	and	opens	space	for	further	
research	[115,	118,	119].	
	
1.6.4 The	monoamines	
The	most	extensive	studies	done	so	far	are	probably	much	more	on	monoamines	DA,	NA	and	5‐
HT	within	the	effective	disorders	disciplinary	area.	
NA	is	abundant	in	the	peripheral	tissues	and	has	both	pre	and	post	synaptic	actions	in	the	CNS	
(α	and	β	receptors)	[120,	121].	Axons	of	NA	cells	in	the	pons	and	medulla	also	extend	into	other	
parts	of	the	brain	and	spinal	cord.		Small	cluster	of	neurons	located	in	the	brain	stem	produces	
adrenaline	 instead	of	NA.	These	cells	 rectify	 to	 the	pons,	medulla	and	 the	hypothalamus.	They	
are	responsible	in	heart	control.	Other	researches	have	also	confirmed	the	association	between	
NA	 in	 the	 brain	 with	 CNS	 and	 control	 of	 blood	 pressure	 and	 or	 heart	 failure	 [120,	 122].	
Amphetamine	 and	 substances	 that	 can	 release	 catecholamine	 in	 the	 brain,	 do	 increase	
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wakefulness	 or	 arousal	 and	 alertness	 [120,	 121].	 Substances	 (like	AMPT)	 that	 can	 antagonize	
catecholamine	are	able	to	counteract	this	effect.		
											 																																											
Fig.1h Noradrenaline	Pathway	
	
Serotonin	(5‐HT)	can	be	found	in	pons	and	the	upper	medulla	in	the	brain,	a	location	known	as	
raphe	nuclei	 [120,	123].	 It	extends	 from	the	nuclei	 to	a	 lot	of	 locations	 in	 the	cortex	 including	
hippocampus,	 basal	 ganglia,	 the	 limbic	 system	 and	 hypothalamus.	 It	 then	 branches	 to	 the	
cerebellum	medulla	 and	 the	 spinal	 cord.	 The	 5‐HT	 receptors	 	 are	 second	messengers	 in	 a	 G‐
protein	 coupled	 pathway	 with	 the	 exception	 of	 5HT3[120,	 124,	 125].	 5‐HT	 has	 subtypes	 of	
receptors	 that	 generate	 either	 inhibitory	 or	 excitatory	 effects.	 	 5‐HT	 can	 cause	 hallucination	
(through	the	5‐HT1	subtype	receptor).	Hallucinogenic	agents	can	also	cause	such	effects.	 	They	
induce	sleep,	arouse	and	mood	disorders.	They	can	cause	depression	according	to	research[123,	
126],	feeding	and	appetite	disorders	[120,	127].	
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Fig.1i Serotonin	Pathway	
Lots	of	 attention	 is	paid	 to	DA	 in	 the	 last	decades.	DA	has	 few	pathways	 in	 the	brain.	The	DA	
pathway	extends	from	the	substantia	nigra	to	the	corpus	striatum	in	the	negrostriatial	pathway.	
From	the	mesocortical	pathway,	 it	extends	 its	origins	 from	the	midbrain	 to	 the	 forebrain.	 It	 is	
also	found	in	the	tubero‐hypophyseal	pathway.	Its	actions	are	through	the	D1	and	D2	receptors.	
Research	cloning	has	revealed	subgroups	through	D1	to	D5	receptors	and	are	G‐coupled	protein	
receptors	[120,	128].	Dopamine	functions	on	motor	systems	(like	Parkinson	diseases)[129]	and	
behavioral	 effects[120].	 	 Amphetamine	 causes	 behavioral	 effects	 and	 can	 be	 antagonized	 by	
dopamine	agents.	Dopamine	agents	are	being	used	in	depression	and	psychiatry[120,	129]	and	
almost	 all	 antidepressants	 increase	DA	 activities[117].	Other	 researches	 have	 also	 proved	 the	
pharmacological	 involvement	 of	 dopamine	 in	 depression[130,	 131],	 and	 also	 in	 sleep	
disorders[132].  Pharmacological	 evidence	 had	 proven	 dopamine	 is	 responsible	 in	 vomiting,	
when	stimulate	the	dopamine	receptors	(specifically	D2)[120]	.	
	
					 	
Fig.1j Dopamine	Pathway	
	
1.6.5 The	BDNF	hypothesis	
BDNF	 belongs	 to	 the	 neurotrophin	 protein	 family	 of	 growth	 factors	 in	 the	 brain	 and	 the	
periphery	 (specifically	 in	 human	 serum	 and	 plasma).	 BDNF	 has	 roles	 in	 neuronal	 outgrowth,	
differentiation,	synaptic	connectivity,	neuronal	condition	and	have	long	been	recognized	in	the	
field	 of	 neuroscience.	 Its	 actions	 are	 through	 the	 tropomycin	 receptor	 kinase	 B	 (TrkB).	 TrkB	
belongs	to	the	tropomycin	receptor	kinase	family	(Trk)	from	the	tyrosine	kinase	receptors.	[133‐
135].		
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BDNF	 has	 also	 been	 reported	 to	 be	 involved	 in	 stress	 and	major	 depression.	 	 Animal	 studies	
have	 shown	 that	 BDNF	 activities	 occur	 in	 patients	 with	 major	 depression	 [134‐137].	 The	
hippocampus	 can	 stimulate	 or	 inhibit	 the	 vasomotor	 center	 and	 have	 therefore	 an	 extremely	
significant	 role	 in	neuroscience.	This	 implies	 that	major	depression	 could	be	 caused	by	BDNF	
degeneration	 (to	 some	 extent)	 in	 the	 hippocampus.	 Scientific	 studies	 have	 shown	 that	
impairment	 BDNF‐TrkB	 receptors	 lead	 to	 poor	 responses	 of	 antidepressant	medication	 [135,	
137].	The	neurotrophic	hypothesis	of	depression	 states	 that	decreased	 levels	of	brain‐derived	
neurotrophic	factors	(BDNF)	are	responsible	for	the	characteristics	seen	in	depressed	patients.	
Antidepressants	 achieve	 their	 therapeutic	 effects	 by	 elevating	 expression	 of	 neurotrophic	
factors	in	the	hippocampus	[135‐137].			
	
	
Fig.1k 	
	
1.6.6 HPA	mechanisms	
Adrenal	 steroid	 (cortisol)	 is	 usually	 synthesized,	 released	 by	 and	 under	 the	 regulation	 of	
adrenocorticotropic	 hormone	 (ACTH).	 The	 corticotrophin‐releasing	 hormone	 (CRH)	 from	 the	
hypothalamus	 stimulates	 the	 pituitary	 glands	 to	 release	 ACTH	 (by	 positive	 feedback),	 whiles	
vasopressin	stimulates	ACTH	release	from	the	posterior	glands	by	circulating	glucocorticoids	in	
the	 blood	 (by	 a	 negative	 feedback).	 This	 system	 is	 often	 called	 the	 hypothalamic‐pituitary‐
adrenal	unit	(HPA).		
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Depressed	 patients	 often	 have	 high	 cortisol	 blood	 level.	 The	 explanation	 to	 this	 high	
concentration	is	due	to	impairment	of	receptors	of	ACTH	or	HPA	as	a	whole.	The	theory	led	to	
the		clinical	test	(termed	as	“dexamethasone	suppression	test”)[98,	100,	138].	The	plasma	level	
of	cortisol	 is	raised	upon	administration	of	synthetic	cortisol	(dexamethasone)	by	a	depressed	
patient.	 Cortisol	 blood	 level	 reduces	 when	 synthetic	 cortisol	 is	 administered	 by	 a	 normal	
individual.	 Although	 some	 experiments	 have	 shown	 higher	 administered	 doses	 of	
dexamethasone	 to	 suppression	of	ACTH	and	cortisol[98,	138],	 this	 shift	 is	due	 to	 the	negative	
feedback	effect	of	impaired		glucocorticoid	receptors	of	dexamethasone	[138].		
The	hypothesis	states	that	depression	disorders	include	changes	in	the	hypothalamic‐pituitary‐
adrenocortical	 (HPA)	 system.	 Causes	 of	 depression	 in	 some	 depressed	 patients	 might	 result	
from	altered	regulation	of	the	HPA	system	[107,	138,	139].	
CRH	 is	 also	 found	 in	 the	 brain.	 Their	 functions	 in	 the	 brain	 are	 unique	 than	 other	 endocrine	
hormones.	 They	 affect	 behavioral	 effects.	 CRH	 can	mimic	 the	 effects	 of	 depression	when	 they	
enter	the	brain[98,	140].	Experimental	studies	 in	animals	have	supported	behavioral	effects	of	
CRH	 activity	 in	 the	 brain	 [138,	 141,	 142].	 Several	 hormones	 like	 gonadal	 hormones,	 thyroid	
hormones,	prolactin	and	growth	hormones	may	cause		depression	[139].	
	
1.6.7 Treatment	of	depression	
Treatment	 of	 depression	 and	 other	 monoamine	 neurotransmitter	 diseases	 is	 not	 possible	 by	
direct	 administration	 of	 monoamine	 neurotransmitters.	 This	 is	 because	 the	 monoamine	
neurotransmitters	 do	 not	 cross	 the	 blood‐brain	 barrier.	 Antidepressant	 agents	 are	 capable	 of	
crossing	the	blood	brain	barrier	[143‐145].	Some	monoamines	can	easily	be	metabolized	before	
they	reach	their	targets.	Transmissions	of	monoamines	and	other	neurotransmitters	in	the	brain	
are	terminated	by	reuptake	(into	the	nerves)	or	metabolized	(by	monoamine	oxidase).	
The	technique	used	in	treatment	of	depression	is	to	increase	the	availability	of	the	transmitters	
in	 the	 brain.	 Research	 has	 shown	 that	 different	mechanisms	may	 increase	 the	 availability	 the	
monoamines.	 These	 include	 blocking	 the	 reuptake	 of	 the	 monoamine	 in	 the	 synapse	 and	 or	
inhibiting	 the	metabolism	of	 the	monoamine	or	 combination	of	both.	The	 fact	 that	 theories	of	
depression	 are	 not	 simple	 has	 led	 to	 a	 wide	 of	 research.	 	 Scientists	 have	 discovered	 a	 lot	 of	
receptors	including	α	and	β	adrenoceptors	(specifically	α2	and	β1	receptors)	that	interact	with	
antidepressant.	 	 	 In	recent	research,	antidepressants	(like	desipramine)	inhibit	the	reuptake	of	
NA,	leading	to	activation	of	both	pre‐	and	postsynaptic	receptors,	including	α1	and	2,	and	β1	and	
2	subtypes	[146].	
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Scientists	 prefer	 classifying	 antidepressants	 by	 function	 rather	 than	 chemical	 structure	 [147,	
148].	 This	 avoids	 the	misinterpretations	 of	 incorrect	 use	 of	 terminologies	 in	 literatures[148].	
Antidepressant	 agents	 are	 classified	 under	 antidepressant	 (N06A)	 according	 to	 the	 Anatomic	
therapeutic	 classification	 of	 drugs	 (ATC	 system)	 under	 the	 subgroup	 of	 N06	 (Psycholeptics)	
[149].		
	
1.6.8 Antidepressants	
Monoamine	 reuptake	 inhibitors	 are	 non‐selective	 reuptake	 inhibitors	 of	 the	 monoamines	
notably	 noradrenaline	 or	 serotonin	 (standard	Tricyclic	 antidepressants).	 The	 TCAs	 have	 been	
one	of	the	oldest	antidepressants	available.	 	They	block	the	reuptake	of	amines	by	competitive	
reaction	 for	 the	 binding	 sites	 of	 the	 neurotransmitters.	 They	 interfere	with	 the	 synthesis	 and	
storage	 of	 the	 amines	 in	 the	 synaptic	 vesicles.	 	 They	 also	 prevent	 other	 neurotransmitter	
receptors;	 example	muscarinic	 acetyl	 choline,	 histamine	 and	 5‐HT.	 	 This	 explains	 some	of	 the	
unpleasant	 side	effects	 like	dry	mouth,	urinary	 retention,	blurred	vision	and	 constipation	 [98,	
148].	
Other	non‐selective	monoamine	reuptake	 inhibitors	(serotonin	noradrenaline	reuptake	SNRIs)	
include	 venlafaxine	 and	 duloxetine.	 Drugs	 in	 this	 group	 inhibit	 the	 neuronal	 uptake	 of	 both	
serotonin	 and	 NA.	 However,	 they	 do	 not	 have	 significant	 affinity	 for	 central	 muscarinic,	
histaminic,	or	α‐adrenergic	receptors.	
Selective	 serotonin	 reuptake	 inhibitors	 (SSRIs)	 (example	 fluoxetine,	 paroxetine,	 citalopram	
sertraline)	are	the	most	commonly	prescribed	antidepressants.	They	appear	more	selectivity	to	
5‐HT	than	over	NA.	They	are	not	recommended	for	combination	with	the	MAOIs	due	to	the	so	
called	serotonin	syndrome	(hyperthermia,	cardiovascular	collapse	and	tremor)[98,	150].  
Selective	 noradrenaline	 uptake	 inhibitors	 (example	 maprotiline,	 reboxetine)	 are	 tricyclic	
norepinephrine‐reuptake	inhibitors	with	anticholinergic	effects.	
Monoamine	 oxidase	 inhibitors	 (MAOIs)	 include	 irreversible,	 non‐competitive	 inhibitors;	 this	
implies	 they	 are	 non‐selective	 to	 either	MAO‐A	 or	MAO‐B	 subtypes	 of	MAO	oxidase	 (example	
phenelzine,	 tranylcypromine	 and	 iproniazid),	 and	 reversible	 MAO‐A	 selective	 inhibitors	
(example	moclobemide).	Their	main	effect	is	to	increase	availability	of	cytoplasmic	monoamines.	
The	mechanism	is	not	well	understood,	but	it	is	believed	they	cause	downregulation	of	both	β‐
adrenoceptors	and	5‐HT	receptors.	 In	normal	people,	 they	cause	an	 increase	 in	motor	activity	
and	euphoria	in	a	few	days[98,	150].	
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Other	miscellaneous	(atypical)	antidepressants	include	mianserin,	mirtazapine	and	trazodone	
Antidepressant	 drugs	 are	 the	 first	 line	 drug	 for	 the	 treatment	 of	 depression.	 New	 drugs	 and	
drugs	under	development	includes	k‐	opioid	receptor	antagonist,	cannabinoid	receptor	agonists,	
melatonin	receptor	agonists,	cytokines,	histone	deacetylase	inhibitors	[150].	
	
1.7 Diabetes,	anxiety	and	depression	
Several	somatic	diseases	frequently	coexist	with	both	anxiety	and	depression	and	are	very	often	
comorbid	[151‐153].	The	prevalence	rates	of	depression	associated	with	illnesses	or	the	somatic	
diseases	may	 vary	 according	 to	 the	 degree	 of	 illness	 and	management	 of	 disease	 itself	 [154].	
There	have	been	several	researches	on	the	association	or	bilateral	relationships	between	mood	
disorders	 and	 the	 development,	 morbidity	 and	 mortality	 associated	 with	 certain	 medical	
conditions	 or	 diseases	 [94,	 155].	 Researchers	 have	paid	 attention	 to	 diabetes	 since	 300	 years	
ago	[156].		
Anxiety	is	an	emotional	state	usually	caused	by	perceived	danger	that	threatens	the	safety	of	an	
individual.	 The	 symptoms	 may	 include	 generalized	 disorders	 (without	 clear	 reason),	 panic	
disorders	 (with	 panic	 attacks	 associated	 with	 somatic	 symptoms),	 phobias,	 post‐traumatic	
stress	and	excessive	stress	disorder	[157,	158].	Anxiety	is	usually	treated	with	anxiolytics	
Mental	disorders	are	usually	assessed	by	registration	of	patient	symptoms,	behavioral	patterns	
in	 specified	 periods,	 by	 either	 interviews	 or	 questionnaires.	 Studies	 have	 previously	 been	
performed	 on	 anxiety	 among	 diabetes	 patients	 with	 different	 strategies.	 Clinically,	 anxiety	 is	
usually	 assessed	 using	 procedures	 in	 accord	 with	 the	 standard	 criteria	 specified	 in	 the	
International	 Classification	 of	 Diseases	 (ICD‐10)	 or	 the	 American	 version	 of	 the	 American	
Psychiatric	Association	(DSM‐IV).	Nowadays	researchers	use	different	methods	including	Health	
surveys,	screening	techniques,		Hospital	Anxiety	and	Depression	Scale	(HADS)	which	are	among		
the	recognized	as	valid	methodology	for	measuring	anxiety	and	depression	symptoms.	The	use	
of	 “harmonic	 international	 criteria"	provides	 confidentiality	 and	 improves	diagnosis	of	mental	
disorders	made	in	global	research	arena	as	a	common	platform		[159].	
A	 systematic	 study	of	 review	by	Grigsby	 et.al	 estimated	 the	prevalence	of	 generalized	 anxiety	
disorders	among	diabetes	to	be	about	14%,	whiles	up	to	40%	had	elevated	symptoms	of	anxiety,	
although	 they	 stated	 clearly	 that	 further	 epidemiological	 studies	 could	 be	 needed	 [160].	
Sometimes	symptoms	of	anxiety	are	so	common	in	patients	with	depressive	disorders,	therefore	
further	screening	may	be	needed	[96].	Some	studies	are	sometimes	conducted	on	both	anxiety	
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and	depression	because	of	diverse	 symptoms	 (and	 coexist	with	each	other	 that	 are	not	 easily	
differentiated)	 [102,	151,	161,	162].	All	 these	studies	 found	a	significant	 relationship	between	
somatic	illness	(including	diabetes),	anxiety	and	depression.	In	a	comparative	studies	of	diabetes	
and	 other	 somatic	 diseases	 made	 from	 a	 sample	 population,	 the	 percentage	 of	 depressed	
individuals	among	diabetic	patients	(20%)	was	higher	than	asthmatic	(12%).	The	percentage	of	
anxiety	was	lower	among	diabetes	(20%)compared	to	asthmatic	(34%)[163].		
	
1.7.1 Diabetes	and	depression	
The	 comorbidity	 of	 diabetes	 and	depression	 becomes	 a	 problem	when	 evidence	 supports	 the	
association	or	risk	factors	between	diabetes	and	depression[156,	164].	Studies	have	enlightened	
the	 difficult	 condition	 (of	 diabetes	 and	 depression)	 to	 be	 severely	 associated	 with	 poorly	
management	 of	 diabetes	 [165‐167].	 Some	 studies	 have	 also	 concluded	 socio‐demographic	
factors	may	also	account	for	the	risk[168].	Other	studies	found	diabetic	patients	with	high	levels	
of	 depressive	 symptoms	 to	 be	 a	 general	 diabetes	 emotional	 distress,	 and	 not	 necessarily	
clinically	related	to	depression[169].	These	studies	suggest	different	methodological	treatments	
instead	 of	 using	 treatments	 for	 depression.	 In	 another	 study	 (of	 assessing	 the	 quality	 of	 life	
among	 diabetic	 patients),	 the	 researchers	 concluded	 that	 depression	 as	 comorbidity	 is	 so	
compelling	 that	 it	 may	 require	 careful	 management.	 This	 is	 because	 depression	 affects	 the	
quality	of	life[163].		
There	are	several	studies	hypothesizing	depression	as	a	risk	 factor	 for	diabetes[170].	Another	
systematic	 review	 estimated	 depression	 in	 type	 2	 diabetes	 to	 be	 17.6%,	 and	 9.8%	 in	 none	
diabetes.	 The	 number	 of	women	 found	 in	 the	 result	was	 higher	 than	men	 (23.8%	 and	 12.8%	
respectively)[171].	There	are	 several	 evidences	 supporting	 relationship	between	diabetes	 and	
depression[7].
                                                       Methodology 
 
27 
 
	
2 Materials	and	Method	
 
2.1 	Materials	
Information	of	dispensed	prescriptions	 from	Norwegian	pharmacies	 (both	public	 and	hospital	
outpatients)	 and	data	 from	 the	Norwegian	 Statistics	 bureau	 (statbank.ssb.no)	 is	 the	 source	 of	
material	as	an	indirect	measure	of	diseases	in	this	thesis.	The	data	are	from	2006.	
All	 information	 on	 dispensed	 and	 dispatched	 prescriptions	 is	 electronically	 archived	 at	 the	
Norwegian	Drug	Prescription	Database	(NorPD),	a	subunit	of	the	Norwegian	Institute	of	Public	
Health.	Drugs	bought	over	 the	counter	 (without	prescription)	at	pharmacies	or	grocery	stores	
and	drugs	from	hospital	inpatients	are	not	included	in	the	archive.	
National	Insurance	provides	coverage	of	essential	expenditures	on	medication	of	a	disease	(that	
needs	prolonged	treatment,	minimally	 three	months	or	 longer).	The	drugs	must	be	prescribed	
on	the	so	called	"blue	prescription"	and	the	doctor	must	verify	both	diagnoses	and	need	of	the	
drugs.	
Drugs	 prescribed	 on	 the	 blue	 prescription	 are	 ought	 to	 specify	 the	 drug	 indication	 for	 the	
disease	(using	a	reimbursement	code;	§	7	for	diabetes	and	§18	for	psychiatry).		
The	data	include	personal	information	as	age,	month	and	year	of	birth,	sex	and	municipality	of	
residence	 of	 individuals.	 	 Information	 of	 the	 drug	 in	 question	 includes	 Part	 No.,	 number	 of	
packages,	 ATC	 group,	 refund	 points,	 price,	 deductible,	 date	 of	 retrieval.	 	 Lastly,	 information	
about	usage	includes	a	number	of	users	(by	sex,	age,	county	or	health	region),	users	per	1	000	
population	 (prevalence	 per	 1	 000),	 population	 foundation	 (by	 gender,	 age,	 county	 or	 health	
region)	and	turnover	in	doses	(DDD	‐	defined	daily	doses).	
The	information	in	the	database	is	not	integrally	traceable	to	the	individual.	
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2.1.1 The	Norwegian	Drug	Prescriptions	Database		
The	database	contains	a	complete	overview	of	all	prescribed	and	dispensed	drugs	(hospitalized,	
nursing,	 old‐age	 homes	 and	 veterinary)	 from	 pharmacies	 since	 2004.	 Personal	 data	 are	
pseudonymously	stored,	meaning	any	personal	information	is	fictitious	(for	protection).	
The	aim	of	the	Prescription	Database	is	to	collect	and	process	data	on	human	and	animal	drug	
use.	Information	from	the	database	can	be	used	for	the	identification	and	quantification	of	drug	
consumption	 and	 changes	over	 time.	The	 authorities	use	 the	 registry	on	 a	 statistical	 basis	 for	
quality	assurance	of	drug	consumption,	overall	supervision,	management	and	planning.	
The	 Prescription	 Registry	 has	 a	 dedicated	website	 (www.reseptregisteret.no)	with	 a	 range	 of	
information	on	dispensed	drugs	from	prescriptions	in	Norway.		
	
2.1.2 Data	security	and	ethics	
As	stated	above,	the	database	is	already	pseudonymized	and	did	not	require	specific	permission	
from	the	Regional	or	Local	Committee	for	Medical	Research	Ethics	nor	from	the	Norwegian	Data	
Inspectorate.	However,	permission	to	use	the	data	was	needed.	
	
2.2 	Method	
The	 file	 for	 the	year	2006	came	 in	an	ASCII	 format	 (text	 format),	 restructured	by	a	FORTRAN	
program	 and	 imported	 into	 an	 SPSS.	 	 Individuals	 in	 the	 entry	 of	 the	 database	 contain	 all	
necessary	values	(including	the	ATC	codes	of	medication)	needed	for	the	analysis.	
Data	from	the	Norwegian	statistical	bureau	containing	the	rest	of	the	population	helped	extend	
the	data	(from	NorPD)	to	include	the	rest	of	the	general	population.		
	
2.2.1 Data	selection	
Drugs	 that	 fall	 under	 the	 group	 N06A	 (antidepressants)	 in	 the	 ATC	 system	 were	 among	 the	
target	 values.	 A10A	 includes	 all	 insulin	 preparations,	 whiles	 A10B	 includes	 all	 oral	 anti	
glycaemia	agents	registered	in	Norway.	
Insulin	(A10A	in	mono	therapy)	classifies	the	individual	as	type	1	diabetes.	Oral	anti	glycaemia	
(A10B	 in	 mono	 therapy)	 classifies	 the	 individual	 as	 type	 2	 diabetes.	Whiles	 A10A	 and	 A10B	
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denote	the	patient	as	type	X	diabetes	(due	to	the	difficulty	to	determine	if	they	are	type	1	or	type	
2).	 	Most	drugs	under	A10B	require	adequate	and	 functional	β‐cells	 functionality.	 It	 is	 logic	 to	
presume	 the	 individuals	 using	 insulin	 and	 oral	 anti	 glycaemia	 as	 type	 2	 diabetes,	 although	
metformin	 can	 have	 indication	 to	 treat	 women	 with	 polycystic	 ovary	 syndrome	 and	 also	
treatment	of	antipsychotic‐induced	weight	gain.	These	indications	are	not	officially	approved	in	
Norway.	
Only	 individuals	 of	 ages	 20‐79	 are	 in	 the	 analysis.	 Individuals	 in	 the	 database	 were	 then	
categorized	 into	 age	 group	 (ranging	 from	 20‐29,	 30‐39	 and	 so	 on).	 	 Individuals	were	 further	
classified	into	the	three	groups	mentioned	above	and	whether	they	received	antidepressants.	
	
2.2.2 Data	exclusion		
Individuals	 of	 ages	 under	 20	 and	 individuals	 of	 ages	 80	 and	 above	 are	 not	 included	 in	 the	
analysis.	 Classifying	 individuals	 below	 20	 years	 of	 age	 into	 diabetes	 and	 related	 conditions	
would	 not	 be	 difficult,	 but	 it	 will	 be	 extremely	 complicated	 in	 regard	 to	 type	 2	 and	 type	 X.	
Secondly;	it	would	not	be	justifiable	to	include	individuals	below	20	years	of	age	with	depressed	
condition	as	a	 result	of	diabetes.	 	 Individuals	of	80	years	and	above	are	not	 included	because	
most	 of	 them	might	 be	 institutionalized.	 It	 would	 be	 difficult	 to	 account	 for	 the	 medications	
prescribed	 to	 individuals	 over	 80	 years	 of	 age.	 Perhaps	 the	 new	 method	 of	 registering	
medication	known	as	“multi	dose”	will	make	it	possible	to	account	for	these	age	groups	of	people	
in	the	near	future.		
	
2.2.3 Statistical	analysis	
The	analysis	of	the	information	in	hand	was	possible	using	SPSS	version	15	(for	analysis),	SPSS	
version	18	(for	analysis	and	color	graphing)	and	Graphpad	Prism	(for	color	graphing).	Analysis	
and	comparison	of	the	three	groups	(type	1,	type	2	and	type	X)	to	the	general	population	is	the	
main	 work.	 The	 general	 population	 is	 a	 control	 group	 in	 the	 analysis	 (Individuals	 without	
diabetes	medication).	
The	 prevalence	 and	 OR	 (frequency	 and	 percentages)	 were	 both	 calculated	 using	 cross	
tabulation.	 Adjusted	 OR	 and	 confidence	 intervals	 were	 then	 calculated	 with	 binary	 logistic	
regression	analysis	(where	age	and	gender	are	categorical	variables	 in	the	overall	calculation).	
In	 the	analysis	of	 age	group,	gender	 is	 the	categorical	variable	 for	adjustment	of	 the	OR	value	
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using	binary	logistic	regression.	 	All	level	of	significant	for	Chi‐squared	p	value	is	>	0.05.	 	Non‐
overlapping	confidence	intervals	between	single	and	multiple	antidepressants	were	interpreted	
as	significant	difference	in	the	association	between	the	various	groups	of	antidiabetic	treatment	
and	use	of	antidepressants.		
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3 Results	
3.1 Descriptive	overview		
The	 general	Norwegian	 population	 according	 to	 the	 database	 is	 4,640,219	 cases	 as	 per	 2006.		
124,	649	individuals	received	any	antidiabetic	medication.	Whereby	32,715	individuals	received	
insulin	 in	 mono	 therapy,	 76,526	 received	 oral	 anti	 glycaemics	 in	 mono	 therapy	 and	 15,408	
received	both	insulin	and	oral	anti	glycaemic	agents.	257,494	received	antidepressants	whereas,	
214,768	received	single	antidepressants	and	42,726	received	multiple	antidepressants.	
	
In	this	analysis,	there	is	a	selection	of	the	Norwegian	population	from	age	group	20‐79,	a	total	of	
n=3,218,357	 (Male	 =	 1609973,	 Female=1608384).	 	 Table	 1a	 shows	 the	 distribution	 of	 age	
groups	in	the	study	population.	
	
The	 analysis	 compares	 individuals	 on	 diabetes	 medication	 with	 the	 rest	 of	 the	 population	
(without	 diabetes	 medication).	 The	 working	 (selected)	 data	 (20‐79	 years)	 will	 hereon	 be	
referenced	to	as	the	general	population.	Individuals	who	received	insulin	in	mono	therapy	might	
be	assumed	having	type	1	diabetes.	Individuals	using	oral	anti	glycaemic	agents	in	mono	therapy	
are	 likely	 patients	 with	 type	 2diabetes,	 and	 individuals	 receiving	 both	 insulin	 and	 oral	 anti	
glycaemia	agents	in	treatment	are	type	X	diabetes.	
	
Among	 the	 general	 population,	 26,346	 individuals	 (0.8%)	 received	 insulin	 treatment	 in	mono	
therapy	 (constituting	 21.5%	 of	 all	 the	 diabetic	 patients).	 63,176	 (2%)	 received	 oral	 anti‐
glycaemics	 in	mono	therapy	(61.9%	of	 the	diabetic	patients)	and	13,539	(0.4%)	received	both	
insulin	 and	oral	 anti‐glycaemics	 (16.6	%	of	diabetic	patients)	 Illustration	 is	 in	 table	1b.	There	
were	a	total	of	57,957	(56.2%)	male	patients	and	45,104	(43.8%)	female	patients.		
A	 total	 of	 187,090	 individuals	 (5.8%)	 in	 the	 general	 population	 received	 one	 antidepressant,	
whiles	37,970	 (1.2%)	 individuals	 received	multiple	 (two	or	more)	antidepressants	 (Table	1c).		
Among	 the	 diabetic	 patients,	 10,482	 (81.7%)	 individuals	 received	 single	 antidepressant	 and	
2,344	(18.3%)	received	multiple	antidepressants.	
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Table 1a Distribution of Age group in working data 
 
Age group  Frequency   Valid % 
20‐29  562819  17.5 
30‐39  692534  21.5 
40‐49  654178  20.3 
50‐59  603311  18.7 
60‐69  416223  12.9 
70‐79  289292  9 
Total   3218357                       100  
		
	
	
	
	
 
Table 1b Distribution of the prevalence of Diabetes medication prescription 
 
Medication type  Frequency of 
individuals   %  in population 
% among diabetes 
individuals 
Insulin  26346  0.8   21.5 
Oral anti‐glycaemia  63176  2,0   61.9 
Insulin +  
oral ant‐glycaemia 
 
13539 
 
0.4  
                 
                     16.6 
Total    
103061                3.2  
               
                     100 
	
	
	
	
Table 1c Distribution of the prevalence of Antidepressant prescription 
 
Medication type  Frequency of 
individuals   %  in population 
% among diabetes 
individuals 
Single  187090  5.8   81.7 
Multiple  37970  1.2   18.3 
Total    
89522   7.0 
 
100 
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3.2 Distribution	of	prescriptions	of	antidiabetic	and	antidepressive	medications		
 
Figures	 3a	 and	 3b	 illustrate	 the	 prevalence	 of	 antidiabetic	 and	 antidepressive	 medications	
according	to	age.	The	values	given	on	the	y‐axis	are	in	absolute	numbers	of	prescription.	
Among	 insulin,	 the	 prescription	 trend	 increases	 from	 ages	 20‐29	 to	 ages	 30‐39.	 From	 30‐39,	
there	is	a	steady	or	slight	rise	(if	not	none)	and	starts	changing	from	ages	60‐69	where	the	trend	
declines.	
There	is	sudden	(steep)	inclination	among	type	2‐diabetes	from	ages	20‐29	up	to	age	group	60‐
69,	 then	a	 full	 declination.	 Likewise,	 there	 is	 a	 rise	 in	 the	prescription	of	 insulin	 and	oral	 anti	
glycaemia	agents	 from	ages	20‐29	up	to	60‐69	and	then	sudden	drop.	 In	all,	 the	declination	of	
the	prescription	prevalence	begins	from	age	group	60‐69. 
 
  
Fig. 3a Prevalence of prescriptions of antidiabetic medications	(in absolute number of counts) 
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The	 prescriptions	 of	 antidepressants	 are	 somehow	 different.	 In	 both	 single	 and	 multiple	
antidepressants,	 the	prescription	 increases	with	 increasing	age.	There	 is	a	rapid	 increase	from	
ages	 20‐29	 up	 to	 ages	 50‐59	 in	 the	 prescriptions	 of	 single	 antidepressant	 than	 multiple	
antidepressants.	In	both	cases,	the	turning	point	is	at	age	group	50‐59.	
 
 
 
 
 
 
Fig.3b Prevalence of prescriptions of antidepressive medications (in absolute number of counts) 
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3.3 Overall	descriptive	and	analysis		
 
 
3.3.1 Prevalence	of	antidepressants	usage	among	patients	with	diabetes	compared	to	the	
general	population		
 
 
 
Table 1 c. Diabetes and usage of single antidepressants compared to the general population 
 
Diabetes 
N of  Diabetes 
(in group) * 
(A) 
N  Diabetes type (using 
single antidepressant) 
(B 
           %   in (B) 
 
% (Non diabetes 
using single 
antidepressants) 
Insulin in 
Mono therapy 
 
25894 
 
  2305 
 
   8.9 
 
    5.7 
Oral anti 
glycaemia in 
 mono therapy 
61673  6439  10.4 
 
   5.7 
Insulin and Oral 
anti glycaemia  13150  1738  13.2 
 
  5.7 
 
 
 
 
	
	
	
Table 1 d. Diabetes and usage of multiple antidepressants compared to the general population 
 
Diabetes 
N  Diabetes 
(in general population) 
(A)* 
N  Diabetes type (using 
multiple antidepressant) 
(B 
           %   in (B) 
 
% (Non diabetes 
using multiple 
antidepressants) 
Insulin in 
Mono therapy  24041  452  1.9 
 
1.2 
Oral anti 
glycaemia in 
 mono therapy 
56737  1503  2.6 
 
1.2 
Insulin and Oral 
anti glycaemia  11801  389  3.3 
 
1.2 
 
	
	
*	Sum	of	individuals	in	diabetes	group	not	using	antidepressant	and	individuals	using	antidepressants.	
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Tables	1c	and	1d	(above)	illustrate	the	descriptive	nature	of	single	and	multiple	antidepressants	
among	perspective	diabetes	and	non‐diabetes	individuals	within	the	general	population.	
	
In	 usage	 of	 single	 antidepressant,	 2,305	 (8.9	 %)	 individuals	 (who	 received	 insulin	 in	 mono	
therapy)	 also	 received	 one	 antidepressant	 compared	 to	 5.7	%	 among	 the	 general	 population	
who	also	received	single	antidepressants.		
Among	 oral	 anti‐glycaemia	 usage,	 6,439	 (10.4%)	 individuals	 received	 one	 antidepressant	
compared	to	5.7	%	among	the	general	population.	Further,	among	individuals	treated	with	both	
insulin	and	oral	anti‐glycaemia	agents,	1,738	individuals	(13.2%)	received	one	antidepressant.	
	
For	 multiple	 antidepressant	 usage,	 452	 individuals	 (1.9%)	 who	 received	 insulin	 (in	 mono	
therapy)	 also	 received	multiple	 antidepressants	 compared	 to	 1.2%	 in	 the	 general	 population.	
The	corresponding	number	for	those	who	received	oral	anti‐glycaemia	and	those	who	received	
both	insulin	and	oral	anti	glycaemia	agents	are	(n=1,503,	2.6%)	and	(n=389,	3.3%)	respectively.	
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3.3.2 Risks	of	antidepressants	usage	among	patients	with	diabetes	compared	to		the	
general	population	
 
 
Table 1 d. Risk of single antidepressant usage among diabetic patients compared to the general 
population 
 
Diabetes	 OR	 Confidence	Interval	 Pearson		Chi‐Squared	
Insulin	in	mono	
therapy	 1.55	 1.49	 1.62	 P<0.001	
Oral	anti	
glycaemia	(in	
mono	therapy)	
1.56	 1.52	 1.60	 P<0.001	
Insulin	and	oral	
anti	glycaemia		 2.0	 1.90	 2.11	 P<0.001	
 
 
 
 
 
Table 1 e. Risk of multiple antidepressant usage among diabetic patients compared to the general 
population 
 
 
Diabetes	 OR	 Confidence	Interval	 Pearson		Chi‐Squared	
Insulin	in	mono	
therapy	 1.52	 1.38	 1.66	 P<0.001	
Oral	anti	
glycaemia	(in	
mono	therapy)	
1.84	 1.74	 1.94	 P<0.001	
Insulin	and	oral	
anti	glycaemia		 2.25	 2.04	 2.50	 P<0.001	
 
 
	
Table	1d	and	1e	shows	the	overall	risks	of	adjusted	OR	values	(from	logistic	regression)	in	the	
usage	of	single	and	multiple	antidepressants	within	perspective	diabetes	types	respectively.	
	
Individuals	 who	 received	 insulin	 only	 had	 OR=1.55	 (95%	 CI:	 	 1.49‐1.62)	 risk	 of	 using	 single	
antidepressant	compared	to	the	general	population.	Likewise,	individuals	who	received	oral	anti	
glycaemic	only	had	OR=1.56	(95%	CI:		1.52‐1.60)	risk	of	using	antidepressants	compared	to	the	
general	population.	Individuals	who	received	both	insulin	and	oral	anti	glycaemia	had	an	OR=2.0	
(95%	CI:		1.9‐2.1)	risk	of	using	antidepressants	compared	to	the	general	population	with	p	value	
<0.001.	
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For	multiple	antidepressant	usage,	individuals	who	received	insulin	only	had	OR=1.52	(95%	CI:	
1.38‐1.66)	risks	compared	to	the	general	population.	Among	individuals	who	received	oral	anti	
glycaemic	 only,	 there	was	 OR	 =	 1.84	 (95%	 CI:	 	 1.74‐1.94)	 for	 using	multiple	 antidepressants	
compared	to	the	general	population.	For	individuals	using	both	insulin	and	oral	anti	glycaemia	
there	was	OR=2.25	(95%	CI:	2.04‐2.50)	compared	to	the	general	population.	
	
	Based	on	non‐overlapping	confidential	intervals	it	can	be	inferred	that	there	was	a	difference	in	
OR	 between	 single	 and	 multiple	 antidepressant	 usage	 for	 diabetic	 patients	 using	 oral	 anti	
glycaemia	agents	in	mono	therapy	(Fig.	3c‐3e)).	
	
	
	
Fig.3c Risk of Antidepressant usage among Insulin users compared to non-diabetes
in the general population
0.5
1.0
1.5
2.0
Insulin
Non diabetes
Si
ng
le 
AD
Mu
ltip
le 
AD
O
R
 (C
I)
In
su
lin
  
                                                         Results 
 
39 
 
Fig.3d Risk of Antidepressant usage among antiglycaemic users compared to non-diabetes
in the general population
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Fig.3e Risk of Antidepressant among anti-glycaemic and insulin users compared to non-diabetes
in the general population
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3.3.3 	Gender	analysis	
	
Among	 individuals	 who	 received	 insulin	 only,	 6.8%	 (n=1,032)	 males	 received	 single	
antidepressants	 in	 contrast	 to	11.9%	(n=1,273)	 females.	 1.5%	 (n=222)	males	 and	2.4%	 (230)	
females	received	multiple	antidepressants.	Among	individuals	who	received	oral	anti	glycaemic	
only,	 7.5	 %	 (n=2,581)	 males	 and	 14.2%	 (n=3,858)	 females	 received	 single	 antidepressants.	
Whiles	1.9%	(n=606)	males	and	3.7%	(n=897)	females	received	multiple	antidepressants.		
However,	 9.7	%	 (n=710)	males	 and	 17.7%	 (n=1,028)	 females	 received	 single	 antidepressants	
among	users	of	both	of	insulin	and	oral	anti	glycaemic	agents.	Whiles	2.3%	(n=159)	males	and	
4.6	%	(n=230)	females	received	multiple	antidepressants.	
	
Using	logistic	regression	with	age	as	a	categorical	variable,	analysis	of	gender	shows	that	there	is	
no	significant	difference.		
The	odds	in	using	single	antidepressants	among	individuals	who	received	insulin	only	was	1.61	
(95%	CI:		151‐171)	in	males,	whiles	females	had	OR=1.52	(95%	CI:		1.44‐1.62).	The	risk	in	using	
multiple	 antidepressants	 among	 males	 was	 1.70	 (95%	 CI:	 1.48‐1.94).	 Whiles	 females	 had	
OR=1.39	 (95%	 CI:	 1.22‐1.58).	 All	 with	 significantly	 increased	 risk	 compared	 to	 the	 general	
population	(p	value	<	0.001).	
The	 odds	 in	 using	 single	 antidepressants	 among	 diabetic	 patients	 using	 oral	 anti	 glycaemic	
agents	 in	mono	 therapy	was	1.56	 (95%	CI:	 	 1.49‐1.62)	 in	males.	Whiles	 females	had	OR=1.58	
(95%	CI:	 1.53‐1.64).	 In	multiple	 antidepressants,	males	had	 an	OR=1.86	 (95%	CI:	 	 1.71‐2.20).	
Whiles	females	with	OR=1.86	(95%	CI:	1.74‐1.99).	All	OR	were	significantly	increased	(p	value	<	
0.001).	
For	 patients	 using	 both	 insulin	 and	 oral	 anti	 glycaemia	 agents,	 the	 odds	 ratio	 in	 using	 single	
antidepressants	among	males	compared	to	the	general	population	was	OR=2.06	(95%	CI:	1.91‐
2.23).	Whiles	females	had	OR=1.98	(95%	CI:		1.85‐2.12).	However,	in	multiple	antidepressants,	
males	had	an	OR=2.33	(95%	CI:	1.99‐2.73).	Whiles	females	had	OR=2.23	(95%	CI:	1.96‐2.55).	All	
OR	were	significantly	increased	(p	value	<	0.001).	
	
In	 general,	 the	 risk	 is	 higher	 for	multiple	 antidepressants	 compared	 to	 single	 antidepressants	
There	were	only	small	differences	in	the	OR’	between	men	and	women.	
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3.4 Analysis	within	age	groups	
3.4.1 Prevalence	of	antidepressants	usage	among	patients	using	insulin	in	monotherapy	
and	non‐diabetics	
 
Table 2 a. Insulin (in mono therapy) and usage of single antidepressants compared to non‐diabetes within 
age groups  
Age group  
(in years) 
N  Type 1 diabetes 
(in general 
population) 
(A)* 
N  Type 1 diabetes (using 
single antidepressant) 
(B 
           %   in 
(B) 
 
% (Non diabetes in 
group using single 
antidepressants) 
20‐29  2970  130  4.4   3.1 
30‐39  4539  280  6.2   4.4 
40‐49  4622  386  8.4   5.9 
50‐59  4660  509  10.9   7.0 
60‐69  4828  523  10.8   7.9 
70‐79  4275  477  11.2   8.5 
 
 
Table 2 b. Insulin (in mono therapy) and usage of multiple antidepressants compared to non‐diabetes within 
age groups  
Age group  
(in years) 
N  Type 1 diabetes 
(in general 
population) 
(A)* 
N  Type 1 diabetes (using 
multiple antidepressant) 
(B 
           %   in 
(B) 
 
% (Non diabetes in 
group using multiple 
antidepressants) 
20‐29  2874  34  1.2   0.6 
30‐39  4332  73  1.7   0.9 
40‐49  4321  85  2.0   1.3 
50‐59  4253  102  2.4   1.5 
60‐69  4396  91  2.1   1.6 
70‐79  3865  67  1.7   1.9 
	
*	Sum	of	individuals	in	age	group	not	using	antidepressant	and	individuals	using	antidepressant.	
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Tables	 2a	 and	 2b	 illustrate	 the	 outcomes	 from	 the	 analysis	 among	 individuals	 who	 received	
insulin	in	mono	therapy,	single	and	multiple	antidepressants.	
	
In	 the	usage	of	 single	 antidepressants,	 cases	 increase	with	 increasing	age.	Although	 there	 is	 a	
slight	decline	from	age	groups	50‐59	(n=509,	10.9%)	to	age	group	60‐69(n=523,	10.8%).	
	
Comparing	the	trend	of	diabetes	individuals	to	the	general	population	(who	did	not	receive	anti	
glycaemia	 agents)	 shows	 that,	 the	 cases	 in	 single	 antidepressant	 usage	 are	 higher	 within	
diabetes	 individuals	 than	 the	 general	 population.	 	 In	 age	 groups	 20‐29;	 130	 cases	 (4.4	 %)	
compares	to	3.1%	in	the	general	population.	In	age	group	30‐39;	(n=280,	6.2%)	compared	to	4.4	
%	 in	 the	 general	 population.	 In	 age	 group	 40‐49;	 (n=386,	 8.4%)	 compared	 to	 5.9%	 in	 non‐
diabetes.		In	age	groups	50‐59	and	60‐69,	the	prevalence	is	higher	in	both	cases	(10.9%	and	10.8	
%	respectively)	compared	to	the	non‐diabetes	(7.0	and	7.9%	respectively).	However,	these	age	
groups	seem	similar.	
	
The	nature	of	the	trend	in	the	prevalence	of	multiple	antidepressants	is	a	little	different,	in	that	
the	decline	appears	to	be	after	age	group	50‐59.	The	prevalence	of	the	cases	increased	steadily	
from	age	group	20‐29	through	50‐59.	The	trend	then	declines	from	age	groups	60‐69.	This	is	in	
both	number	and	percentage	column.	The	cases	of	diabetes	individuals	are	twice	as	the	general	
population.	Age	groups	20‐29	(1.2	%	compared	to	0.6	%)	in	the	general	population,	30‐39	(1.7%	
compared	to	0.9. 
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3.4.2 Risks	of	antidepressants	usage	among	patients	using	insulin	in	monotherapy	
compared	to	non‐diabetic	s	
 
 
Table 2 c. Risk of single antidepressant usage among patients using insulin in monotherapy compared to 
non‐diabetics within age groups  
 
Age	group	(in	years)	 OR	 Confidence	Interval	 Pearson		Chi‐Squared	
20‐29	 1.46	 1.23	 1.75	 P<0.001	
30‐39	 1.50	 1.32	 1.69	 P<0.001	
40‐49	 1.57	 1.41	 1.74	 P<0.001	
50‐59	 1.78	 1.62	 1.95	 P<0.001	
60‐69	 1.58	 1.44	 1.74	 P<0.001	
70‐79	 1.41	 1.28	 1.55	 P<0.001	
 
 
 
 
Table 2 d. Risk of multiple antidepressant usage among patients using insulin in monotherapy compared to 
non‐diabetics within age groups  
 
Age	group	(in	years)	 OR	 Confidence	Interval	 Pearson		Chi‐Squared	
20‐29	 1.93	 1.40	 2.70	 P<0.001	
30‐39	 1.91	 1.52	 2.41	 P<0.001	
40‐49	 1.61	 1.30	 2.00	 P<0.001	
50‐59	 1.71	 1.41	 2.10	 P<0.001	
60‐69	 1.48	 1.20	 1.82	 P<0.001	
70‐79	 0.994	 0.78	 1.27	 P=0.96	
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The	values	(tables	2c	and	2d)	are	OR	values	adjusted	from	the	binary	logistics	regression	model.	
In	the	usage	of	single	antidepressants	among	insulin	dependent	diabetes,	age	group	20‐29	had	
OR	 =	 1.46	 (95%	 CI:	 1.23‐1.75)	 risk	 compared	 to	 the	 general	 population.	 In	 age	 group	 30‐39	
OR=1.5	 (95%	 CI:	 1.32‐1.69),	 whiles	 age	 group	 40‐49	 have	 OR=1.57	 (1.41‐1.74).	 All	 OR	 were	
significantly	 increased	(p	value	<	0.001).The	OR	value	is	somehow	higher	in	the	age	group	50‐
59;	 1.78	 (95%	 CI:	 	 1.62‐1.95),	 then	 the	 value	 falls	 from	 age	 groups	 60‐69	 OR=1.58	 (95%	 CI:		
1.44‐1.74)	 through	 70‐79	 with	 OR	 =	 1.41	 (95%	 CI:	 	 1.28‐1.55).	 All	 OR	 were	 significantly	
increased	(p	value	<	0.001).	
	
	
In	 the	 multiple	 antidepressant	 usage	 among	 users	 of	 insulin	 only,	 the	 OR	 values	 are	 in	
decreasing	order	with	 increasing	 age	 (up	 to	 age	 group	40‐49).	Age	 group	20‐29	had	OR=1.93	
(95%	CI:	1.40‐2.7).	Age	group	30‐39	had	OR=1.91(95%	CI:	1.52‐2.41).	Age	group	40‐49	had	OR=	
1.61	(95%	CI:		1.30‐2.0).	The	trend	changes	from	age	group	50‐59	with	OR=1.71	(95%	CI:	1.41‐
2.10).	 In	 age	 group	 60‐69	 the	 risk	 declines	 again	 with	 OR=1.48	 (95%	 CI:	 1.20‐1.82).	 All	 had	
significant	p	value	<0.001.	Age	group	70‐79	had	OR=0.994	(95%	CI:		0.78‐1.27).	The	p	value	of	
70‐79	is	also	0.96	(not	significant).	
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Fig.3f. Risk of Insulin and antidepressant usage compared with non-diabetes
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3.4.3 Prevalence	of	antidepressants	usage	among	patients	using	oral	anti	glycaemic	
agents	only	compared	to	non‐diabetic	s	
 
 
Table 3 a. Oral anti‐glycaemia (in mono therapy) and usage of single antidepressants compared to non‐
diabetics within age groups  
 
Age group  
(in years) 
N  Type 2 diabetes 
(in general 
population) 
(A)* 
N Type 2 diabetes (using 
single antidepressant) 
(B 
           %   in 
(B) 
 
% (Non diabetes in 
group using single 
antidepressants) 
20‐29  1098  72  6.6   3.1 
30‐39  3184  335  10.5   4.4 
40‐49  6806  820  12.0   5.9 
50‐59  14402  1679  11.7   7.0 
60‐69  19036  1801  9.5   7.9 
70‐79  17147  1732  10.1   8.7 
 
 
 
Table 3 b. Oral anti‐glycaemia (in mono therapy) and usage of multiple antidepressants compared to non‐
diabetics within age groups  
 
Age group  
(in years) 
N  Type 2 diabetes 
(in general population) 
(A)* 
N  (Type 2 diabetes using 
multiple antidepressant) 
(B 
           %   in (B) 
 
% (Non diabetes in 
multiple group using 
antidepressants) 
20‐29  1043  17  1.6   
0.6 
30‐39  2942  93  3.2   
0.9 
40‐49  6220  234  3.8   
1.3 
50‐59  13147  424  3.2   
1.5 
60‐69  17605  370  2.1   
1.6 
70‐79  15780  365  2.3   
1.9 
 
*	Sum	of	individuals	in	age	group	not	using	antidepressant	and	individuals	using	antidepressants.	
 
	
	
	
                                                         Results 
 
47 
 
Among	 individuals	 who	 received	 oral	 anti	 glycaemic	 agents	 only,	 the	 trend	 shows	 double	
percentage	in	cases	of	diabetes	compared	to	the	general	population.	The	cases	in	age	group	20‐
29	 (n=	 72,	 6.6%)	 are	 doubled	 compared	 to	 3.1%	 in	 the	 general	 population.	 Age	 group	 30‐39	
(n=335,	10.5%)	 is	also	higher	compared	 to	4.4	%.	Age	group	40‐49	(n=	820,	12	%)	compared	
5.9%	in	the	general	population.	However,	 the	trend	in	age	groups	50‐59	(n=1679,	11.7%)	and	
60‐69	(n=1801,	9.5	%)	looks	similar,	but	the	differences	compared	to	the	general	population	is	
still	 high.	 This	 trend	 is	 somehow	 strange	 in	 age	 groups	 70‐79	 (n=1732,	 10.1%)	 where	 the	
prevalence	of	cases	increases	after	declining	at	age	group	60‐69	(Table	3a).	
	
In	 the	 usage	 of	multiple	 antidepressants	 among	 individuals	who	 received	 oral	 anti	 glycaemic	
agents	only,	the	number	of	cases	increases	(in	percentage),	almost	double	or	triples	compared	to	
the	general	population.	The	cases	in	age	group	20‐29	(n=17,	1.6%)	is	higher	compared	to	0.6%	
among	the	general	population.	Cases	in	age	groups	30‐39	(n=93,	3.2%)	is	also	high	compared	to	
0.9%,	 cases	 in	 40‐49	 (n=234,	 3.8%)	 compared	 to	 1.3%	 is	 also	 high.	 Finally,	 cases	 in	 50‐59	
(n=424,	3.2%)	are	high	compared	to	1.5%	compared	to	the	general	population.	The	trend	then	
changes	by	declining;	at	age	groups	60‐69	(n=370,	2.1%)	also	high	compared	to	1.6%,	and	in	age	
group	 70‐79	 (n	 =365,	 2.3	 %)	 compared	 to	 1.9%	 in	 the	 general	 population.	 There	 is	 no	
substantial	difference	in	the	cases	between	age	groups	60‐69	and	70‐79	(Table	3b).	
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3.4.4 Risks	of	antidepressants	usage	among	patients	using	oral	anti	glycaemic	agents	only	
compared	to	non‐diabetics				
 
 
 
Table 3 c. Risk of single antidepressant usage among oral anti glycaemia individuals (in monotherapy) 
compared to non‐diabetes within age groups  
Age	group	(in	years)	 OR	 Confidence	Interval	 Pearson		Chi‐Squared	
20‐29	 1.83	 1.44	 2.32	 P<0.001	
30‐39	 2.42	 2.16	 2.71	 P<0.001	
40‐49	 2.32	 2.16	 2.50	 P<0.001	
50‐59	 1.92	 1.82	 2.02	 P<0.001	
60‐69	 1.34	 1.28	 1.41	 P<0.001	
70‐79	 1.24	 1.18	 1.31	 P<0.001	
 
 
 
 
 
Table 3 d. Risk of multiple antidepressant usage among oral anti glycaemia individuals (in monotherapy) 
compared to non‐diabetes within age groups  
Age	group	(in	years)	 OR	 Confidence	Interval	 Pearson		Chi‐Squared	
20‐29	 2.25	 1.39	 3.64	 P<0.001	
30‐39	 3.32	 2.70	 4.10	 P<0.001	
40‐49	 3.10	 2.71	 3.53	 P<0.001	
50‐59	 2.33	 2.11	 2.57	 P<0.001	
60‐69	 1.49	 1.34	 1.66	 P<0.001	
70‐79	 1.32	 1.18	 1.47	 P<0.001	
 
	
Analytical	results	from	the	regression	model	of	oral	antidiabetic	agents	(in	monotherapy),	single	
and	multiple	antidepressant	usage	are	in	tables3	c	and	3d.	
In	single	antidepressant	usage,	the	risk	decreases	with	increasing	age	from	age	group	30‐39.	Age	
groups	20‐29	had	OR=1.83	(95%	CI:		1.44‐2.32).	Age	group	30‐39	had	OR=2.42	(95%	CI:		2.16‐
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2.71).	Age	group	40‐49	had	OR=2.32	(95%	CI:	2.16‐2.50).	Age	group	50‐59	had	OR	=1.92	(95%	
CI:	1.82‐2.02).	Age	group	60‐69	had	OR=1.34	(95%	CI:	1.28‐1.41)	and	70‐79	had	OR=1.24	(95%	
CI:	1.18‐1.31)	all	with	significant	p	value	<0.001.	
	
In	multiple	 antidepressant	usage,	 the	 risk	also	 increases	with	 increasing	age	until	30‐39,	 then	
declines	again	with	 increasing	age	group.	Age	group	20‐29	had	OR=2.25	 (95%	CI:	 	1.39‐3.64).	
Age	group	had	30‐39	OR=3.32	(95%	CI:	2.70‐4.10).	Age	group	40‐49	had	OR=3.10	(95%	CI:	2.71‐
3.53).	Age	group	50‐59	had	OR=2.33	(95%	CI:	2.11‐2.57).	Age	group	60‐69	had	OR=1.49	(95%	
CI:	 1.34‐1.66).	 Age	 group	 70‐79	 had	 OR=1.32	 (95%	 CI:	 1.18‐1.47).	 All	 OR	 were	 significantly	
increased	(p	value	<	0.001).	
	
	
	
 
 
Fig.3g Risk of Oral anti-glycaemic and antidepressant usage compared with non-diabetes
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3.4.5 Prevalence	of	antidepressants	usage	among	patients	using	both	insulin	and	oral	
anti	glycaemic	agents	compared	to	non‐diabetics	
 
 
Table 4 a. Insulin and oral anti glycaemia (in multi therapy) and usage of single antidepressants compared 
to non‐diabetes within age groups  
Age group  
(in years) 
N  Type X diabetes 
(in general population) 
(A)* 
N  Type X diabetes (using 
single antidepressant) 
(B 
           %   in (B) 
 
% (Non diabetes in 
single group using 
antidepressants) 
20‐29  118  16  13.6   3.1 
30‐39  525  78  14.9   4.4 
40‐49  1444  232  16.1   5.9 
50‐59  3250  451  13.9   7.0 
60‐69  4362  531  12.2   7.9 
70‐79  3451  430  12.5   8.7 
 
 
 
 
Table 4 b. Insulin and oral anti glycaemia (in multi therapy) and usage of multiple antidepressants 
compared to non‐diabetes within age groups  
Age group  
(in years) 
N  Type X diabetes 
(in general population) 
(A)* 
N  Type X diabetes (using 
multiple antidepressant) 
(B 
           %   in (B) 
 
% (Non diabetes in 
group using multiple 
antidepressants) 
20‐29  103  1  1   0.6 
30‐39  446  19  4.1   0.9 
40‐49  1275  63  4.9   1.3 
50‐59  2925  126  4.3   1.5 
60‐69  3925  93  2.4   1.6 
70‐79  3108  87  2.8   1.9 
 
 
 
*	Sum	of	individuals	in	age	group	not	using	antidepressant	and	individuals	using	antidepressants.	
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The	 usage	 of	 single	 antidepressants	 in	 the	 case	 of	 patients	 using	 both	 insulin	 and	 oral	 anti	
glycaemic	agents	is	also	higher.	The	number	of	cases	triples	in	almost	all	age	groups	compared	
to	the	general	population.	In	age	group	20‐29	(n=16,	13.6%)	compared	to	3.1	%,	age	group	30‐
39	(n=78,	14.9)	compared	to	4.4%,	age	group	40‐49	(n	=	232,	16.1%)	compared	to	5.9%	in	the	
general	population.		The	trend	then	declines	from	age	group	50‐59	(n	451,	13.9%)	compared	to	
7%,	age	group	60‐69	(n=	531,	12.2%)	compared	to	7.9%	and	70‐79	(n=430,	12.5%)	compared	to	
8.7%	in	the	general	population.	However,	there	is	no	substantial	difference	in	the	prevalence	of	
cases	from	age	groups	60‐69	to	70‐79,	(Table	4a).	
	
In	 the	analysis	of	multiple	antidepressants	 (table	4.b),	 the	prevalence	of	 cases	 in	 group	30‐39	
(19,	4.1%)	is	almost	five	times	higher	compared	to	0.9%	in	the	general	population.	There	is	no	
difference	in	the	cases	of	age	group	20‐29	(n=1,	1%)	compared	to	the	general	population	(0.6%).	
It	 is	 obvious	 that	 the	 risk	 in	 this	 age	 group	 is	 insignificant.	 However,	 the	 prevalence	 of	 cases	
tripled	in	age	group	40‐49	(n=63,	4.9%)	compared	to	the	general	population	(1.3%).	Age	group	
50‐59	(n=126,	4.3%)	is	also	higher	compared	to	the	general	population	(1.5%).	However,	there	
is	a	declination	from	age	group	60‐69	(93,	2.4%)	and	a	sudden	increase	in	70‐79(n=87,	2.8%)	all	
of	 which	 are	 higher	 compared	 to	 the	 general	 population	 (1.6%	 and	 1.9%	 respectively).	
Illustration	is	given	in	table	4b.	
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3.4.6 Risks	of	antidepressants	usage	among	patients	using	both	insulin	and	oral	anti	
glycaemic	agents	compared	to	non‐diabetics		
 
 
Table 4 c. Risk of single antidepressant usage among patients using both Insulin and oral anti glycaemic 
agents compared to non‐diabetes within age groups  
 
Age	group	(in	
years)	 OR	 Confidence	Interval	
Pearson		
Chi‐Squared	
20‐29	 4.60	 2.71	 7.81	 P<0.001	
30‐39	 3.86	 3.03	 4.92	 P<0.001	
40‐49	 3.30	 2.86	 3.81	 P<0.001	
50‐59	 2.32	 2.10	 2.57	 P<0.001	
60‐69	 1.76	 1.60	 1.93	 P<0.001	
70‐79	 1.54	 1.39	 1.71	 P<0.001	
 
 
 
 
 
Table 4 d. Risk of multiple antidepressant usage among patients using both Insulin and oral anti 
glycaemic agents compared to non‐diabetes within age groups 
 
Age	group	(in	years)	 OR	 Confidence	Interval	 Pearson		Chi‐Squared	
20‐29	 1.47	 0.21	 10.52	 P=0.703	
30‐39	 4.60	 2.90	 7.29	 P<0.001	
40‐49	 4.18	 3.24	 5.40	 P<0.001	
50‐59	 3.13	 2.61	 3.75	 P<0.001	
60‐69	 1.66	 1.35	 2.04	 P<0.001	
70‐79	 1.56	 1.26	 1.93	 P<0.001	
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Analytical	 results	 from	 the	 regression	 model	 of	 patients	 using	 both	 insulin	 and	 oral	 anti	
glycaemia	agents,	single	and	multiple	antidepressant	usage	are	in	tables	4c	and	4d.	
 
The	 risk	 in	 using	 single	 antidepressants	 among	 patients	 using	 both	 insulin	 and	 oral	 anti	
glycaemia	agents	decreases	with	increasing	age	group.	The	risk	values	for	age	groups	20‐29	is	
OR=4.60	(95%	CI:	 	2.71‐7.81).	Age	group	30‐39	had	OR=3.86	(95%	CI:	3.03‐4.92).	Age	groups	
40‐49	had	OR=3.30	 (95%	CI:	 	2.86‐3.81).	Age	groups	had	50‐59	OR=2.32	 (95%	CI:	2.10‐2.57).	
Age	groups	60‐69	had	OR=1.76	(95%	CI:	 	1.60‐1.93).	Age	groups	70‐79	had	OR=1.54	(95%	CI:	
1.39‐1.76).	All	OR	were	significantly	increased	(p	value	<	0.001).	
	
	
In	 multiple	 antidepressants,	 the	 trend	 varies.	 Age	 group	 20‐29	 had	 OR=1.47	 (95%	 CI:	 0.21‐
10.52)	with	 p	 value	0.7	 (not	 significantly	 important).	 The	 risk	 then	decreases	with	 increasing	
age.	Age	group	30‐39	had	OR=4.60	(95%	CI:	2.90‐7.29).	Age	group	40‐49	had	OR=4.18	(95%	CI:	
3.24‐5.40).	Age	groups	50‐59	had	OR=	3.13	(95%	CI:	2.61‐3.75).	Age	groups	60‐69	had	OR=1.66	
(95%	 CI:	 1.35‐2.04).	 	 Age	 group	 70‐79	 had	 OR=	 1.56	 (95%	 CI:	 1.26‐1.93).	 All	 OR	 were	
significantly	increased	(p	value	<	0.001).	
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Fig.3h Risk of oral anti-glycaemic + Insulin and antidepressant usage compared with the
general population
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The point of multiple antidepressants among age group 20‐29 is removed since this is not significant and over estimates 
the graph.
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4. Discussion	
This	section	has	two	sub‐chapters.	First,	 the	discussion	approaches	the	strength,	 limitations	of	
the	 thesis	 and	 tackles	 also	 the	 problems	 concerning	 bias	 and	 or	 confounding	 that	 may	 have	
influenced	the	thesis	in	any	dimension.	Next,	the	section	discusses	the	main	findings/results	and	
the	impact	of	the	work.	
	
4.1 		Methodological	limitations	and	strength		
4.1.1 Study	design	
The	study	has	a	cross‐sectional	design,	measuring	the	relationships	between	various	factors	and,	
measures	 the	 prevalence	 of	 a	 disease	 at	 a	 time	 (normally	 a	 short	 period	 of	 time).	 This	 study	
deals	 with	 the	 relationship	 between	 diabetes	 and	 depression	 as	 measured	 by	 the	 use	 of	
medicine	 used	 to	 treat	 the	 two	 diseases.	 It	 further	 studies	 whether	 this	 association	 varies	
according	to	age	and	gender.	
Although	cross‐sectional	studies	may	have	advantages	in	that,	it	is	fast	and	cost	effective,	there	is	
some	weaknesses	[172].		One	of	the	critical	limitations	of	cross‐sectional	design	is	the	difficulty	
in	 drawing	 conclusions	 regarding	 causality.	 	 One	 can	 only	 conclude	 there	 is	 a	 mono	 or	
multilateral	 relationships	 between	 the	 cause	 and	 result	 [172].	 However,	 it	 will	 be	 hugely	
beneficial	to	implement	a	follow‐up	(in	a	future	study)	and	perform	other	factors	into	account.	
Bias	 is	 a	 systematic	 error	 that	 could	 occur	 in	 epidemiological	 studies	 due	 to	 incorrect	
estimations	or	prediction	of	factors	and	can	affect	risk	of	an	outcome.	
	
4.1.2 Information	Bias	
Information	bias	does	occur	when	information	are	wrongly	registered	as	a	result	of	errors	about	
subjects	or	from	subjects.	Incorrect	information	or	measurement	might	lead	to	wrong	result	that	
could	 further	 lead	 to	 a	 systematic	 error	 [172,	 173].	 We	 used	 medication	 as	 an	 indication	 of	
disease,	and	this	gives	an	imprecise	measure	of	the	disease.	Nevertheless,	it	is	unlikely	that	this	
error	 differs	 according	 to	 subgroups	 in	 the	 study	 population,	 and	 this	 reduces	 the	 risk	 of	
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information	bias.	 Further,	 the	 statistical	 analysis	was	performed	 several	 times	and	 the	 results	
cross	checked	and	registered.	
	
4.1.3 Selection	Bias	
The	 fact	 that	 the	 study	 used	 the	 complete	Norwegian	 population	 seems	 to	 give	 it	 strength	 in	
determining	the	outcomes.		
Selection	 bias	 is	 also	 a	 systematic	 error	 that	 could	 result	 from	 the	 procedures	 of	 selecting	
subjects	 or	 selection	 from	 factors	 that	 influence	 the	 study[172,	 173].	 There	 is	 no	 statistical	
method	that	can	correct	selection	bias.	Selection	of	age	group	from	20‐79	seem	reasonable.	As	
stated	 earlier,	 individuals	 below	 20	 years	 of	 age	 are	 not	 included	 due	 to	 the	 difficulty	 in	
categorizing	them	under	diabetic	type	and	presuming	they	are	suffering	from	depression	related	
illnesses.	 It	 would	 not	 be	 appropriate	 to	 presume	 individuals	 less	 than	 15	 years	 of	 age	 are	
suffering	from	depression.	
Individuals	 above	 80	 years	were	 also	 excluded	 because	most	 of	 them	 are	 in	 old	 age	 home	 or	
institutionalized.	There	is	no	definite	method	of	accounting	for	the	medication	received	by	these	
age	groups.	
Selection	of	Individuals	(variable	is	according	to	the	medication	received.	That	is;	 i)	those	who	
received	 insulin	 only,	 (ii)	 those	who	 received	 oral	 anti	 glycaemia	 agents	 only,	 (iii)	 those	who	
received	 both	 insulin	 and	 anti‐glycaemia	 agents	 and	 (iv)	 those	 who	 received	 none	 of	 the	
diabetes	medications	(as	a	control	group).	Secondly	individuals	were	cross	checked	according	to	
whether;	 (i)	 received	 single	 antidepressant,	 (ii)	 received	 multiple	 antidepressants	 or	 (iii)	
received	none.	 	 The	probability	 values	were	 then	 calculated	 and	 adjusted	with	 binary	 logistic	
regression	 (where	 age	 and	 gender	 are	 part	 of	 the	 applicable	 covariates).	 Some	 oral	 anti‐
glycaemia	agents	can	be	used	or	are	in	use	for	the	treatment	of	polycystic	ovary	syndrome	[174‐
176]and	also	 for	 the	 treatment	of	antipsychotic‐induced	weight	gain[177‐179]	 in	children	and	
adolescents[180].	These	indications	are	not	officially	approved	in	Norway.	
Comparing	 individuals	 of	 perspective	 diabetes	 groups	 to	 the	 general	 population	who	 have	 no	
diabetes	seems	also	justifiable.	This	minimizes	the	errors	that	would	have	resulted	from	having	
diabetes	individuals	among	the	mix	of	non‐diabetics.	
Lastly	the	population	is	homogeneous	enough	to	consider	the	sample	normally	distributed.	
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4.2 	Confounding	
Variables	 that	 can	 associate	with	 both	 the	 risk	 factor	 and	 result	 or	 outcome	 are	 confounders.	
Confounder	 can	 interfere	 significantly	with	 results	 in	 epidemiological	 studies	 [172,	 173].	 Age	
and	 sex	 are	 usually	 the	 standard	 confounders.	 Adjusting	 for	 the	 Odds	 ratio	 with	 age	 and	 or	
gender	where	applicable	avoided	these	confounding	factors.		
One	 limitation	 of	 this	 thesis	 is;	 factors	 related	 to	 lifestyle	 could	 affect	 results.	 No	 adjustment	
made	concerning	BMI,	current	income,	physical	activities,	current	smoking,	CHD,	obesity,	other	
chronic	diseases	(such	as	asthma)	or	other	health	problems.	These	problems	could	be	another	
challenge	 in	 a	 follow‐up	 study.	 There	 is	 no	 need	 to	 adjust	 for	 health	 care	 expenditure	 as	 the	
Norwegian	public	health	care	covers	for	all	chronic	diseases.	
Lastly	 it	 is	 difficult	 to	 determine	 whether	 diabetes	 or	 depression	 is	 the	 first	 onset	 disease.	
Logically,	 depression	 or	 diabetes	 may	 be	 an	 onset	 of	 each	 other	 as	 there	 are	 multiple	 of	
evidences	 supporting	 both	 hypotheses.	 Diabetes	 is	 a	 chronic	 disease	 (and	 lasts	 for	 life)	 and	
mood	disorders	swings	(in	episodic).	Some	people	had	gone	through	depression,	recovered,	and	
may	or	may	not	have	depression	later	in	their	life[181].	Unfortunately,	not	everybody	reports	or	
complain	 about	 depression[181]	 and,	 this	 could	 lead	 to	 serious	 conditions.	 Whether	 all	
physicians	used	appropriate	diagnostic	 tools	 for	 the	detection	of	depression,	 (among	diabetes	
patients)	remains	a	question.	We	assume	that,	since	the	right	indication	of	the	disease	is	on	the	
prescription,	the	individual	who	received	antidepressant	suffers	from	depressive	disorders.	
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4.3 		Main	discussion	
Diabetic	 patients	 have	 long	 been	 known	 to	 have	 twice	 the	 risk	 of	 developing	 depression	
compared	 to	 non‐diabetic	 individuals[182,	 183]	 in	 some	 instances	 1.5‐2.5	 times	 the	 risk[184,	
185].	Several	studies	have	suggested	different	factors	playing	role	in	development	of	depression	
among	diabetes	and	vice	versa.	Several	factors	(as	age,	gender,	marital	status,	educational	level	
or	 income)	 are	 also	 	 known	 to	have	an	 impact	 on	depressive	 	 symptoms,	 and	 thus	affects	 the	
quality	 of	 life	 [186,	 187].	 Depression	 itself	 can	 impair	 attributes	 of	 human	 life[181].	 In	 a	
worldwide	 survey	 conducted	 by	 World	 Health	 Survey,	 9.3%	 (7.3–11.3)	 of	 respondents	 with	
diabetes	had	depression[188].		
This	section	deals	with	the	main	discussion	of	the	comprehensive	analysis	and	then	age	group	
analysis	in	regard	to	diabetes	types,	depression	and	the	use	of	antidepressants.		
	
4.3.1 Overall	analysis	 of	antidepressant	usage	among	diabetic	 individuals	 compared	 to	
the	general	population	
In	 the	 usage	 of	 single	 antidepressant,	 the	 OR	 values	 for	 insulin	 individuals	 (possibly	 type	 1	
diabetes)	was	 1.55,	 for	 users	 of	 oral	 anti	 glycaemic	 only:	 1.56	 and	 for	 individuals	 using	 both	
insulin	 and	 oral	 anti	 glycaemic	 agents:	 2.0.	 The	 values	 for	 both	 insulin	 users	 only	 and	 oral	
antidiabetic	users	only	 are	not	 far	 from	 the	ones	 reported	by	Andersen	et	 al.	 (in	 a	 systematic	
review)[182],	but	in	accord	with	other	findings[7].	The	value	for	users	of	both	insulin	and	oral	
anti	glycaemic	agents	is	somehow	equivalent	to	the	values	reported	in	some	systematic	reviews.	
In	the	usage	of	multiple	antidepressants,	the	OR	value	for	insulin	users	only	(type	1	diabetes)	is	
1.52.	This	value	is	also	not	far	from	the	data	reported	in	the	systematic	review.	The	OR	value	is	
not	surprising	since	the	prevalence	is	not	exceptionally	high	compared	those	who	received	anti	
glycaemic	 only	 and	 to	 those	 who	 received	 both	 insulin	 and	 anti	 glycaemic.	 The	 values	 of	
individuals	using	oral	anti	glycaemic	agents	only	and	for	individuals	using	both	insulin	and	oral	
anti	 glycaemic	 agents	 are	 both	 high:	 1.84	 (95%	CI:	 	 1.74‐1.94)	 and	 2.25	 (95%	CI:	 	 2.04‐2.50)	
respectively.	
The	 overall	 OR	 values	 obtained,	 indicates	 that	 there	 is	 an	 association	 between	 diabetes	 and	
depression.		There	should	be	caution	although,	in	determining	and	finalizing	the	risk	factors	as	
being	 the	 main	 causes	 of	 diabetes	 and	 depression.	 Several	 factors	 related	 to	 human	 lifestyle	
could	contribute	to	the	risks.	 In	a	meta‐analysis,	 	 they	concluded	that	diabetes	 is	 	a	risk	 factor	
and	 can	 potentiate	 depression[182],	 in	 other	 studies	 depression	 eventuates	 from	 diabetes	
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complications[189]	and	poor	glycaemia	control[167].	Other	studies	 found	depression	 to	be	an	
onset	 for	 diabetes	mellitus[164,	 190],	 whiles	 in	 some	 studies,	 no	 evidence	 of	 diabetes	 as	 the	
cause	 depression	 [190,	 191].	 In	 one	 recent	 publication	 (in	 a	 drug	 usage	 methodology),	 they	
found	no	linkage	of	depression	as	a	risk	factor	for	diabetes,	but	rather	the	use	of	antidepressants	
is	due	to	the	burden	of	the	disease,	newly	diagnosed	and	start	of	anti‐glycaemia	agents[192].	
	
Type	 1	 diabetes	 usually	 debuts	 at	 earlier	 ages.	 Newly	 diagnosed	 person	with	 type	 1	 diabetes	
could	be	 a	burden.	One	 can	 assume	 (on	psychosocial	 factors)	 that	 type	1	diabetes	 individuals	
could	also	become	depressed	(in	the	 long	run)	while	dealing	with	 	management	of	 the	disease	
from	 a	 younger	 age.	 Starting	 maintenance	 of	 diabetes	 earlier	 could	 also	 help	 reduce	 future	
complications	and	depression[193].	The	findings	in	this	study	indicate	that	there	is	risk	of	using	
antidepressants	among	individuals	using	insulin	in	monotherapy.		
The	OR	value	of	the	single	antidepressants	among	users	of	insulin	only	is	almost	the	same	as	that	
in	multiple	antidepressant	usage.	The	question	then	arises,	is	the	use	of	multiple	antidepressants	
necessary?	 Does	 their	 depression	 scale	 mandate	 the	 use	 of	 multiple	 antidepressants?	 Is	
depression	the	onset	of	diabetes	type	1?		
The	 risk	 comparison	 in	 the	 regression	 model	 shows	 that	 using	 single	 antidepressants	 was	
significant	 over	 multiple	 antidepressants	 (p<0.001	 vs.	 p=0.67).	 In	 other	 words,	 multiple	
antidepressants	usage	is	insignificant.	These	OR’s	can	be	considered	as	insignificantly	different	
since	the	confidence	intervals	are	overlapping	(Fig.3c).		
Several	 chronic	 diseases	 co‐morbid	 with	 depression[151,	 188].	 Should	 depression	 among	
diabetes	 be	 treated	 with	 caution	 or	 differently?	 Treating	 depression	 sometimes	 needs	 a	
combination	 of	 multiple	 antidepressants	 to	 achieve	 full	 therapeutic	 effects	 [105,	 148]	 and	
treatment	with	 antidepressants	 is	 only	 successful	 in	 about	 50‐60%	of	 individuals[194].	These	
could	also	be	some	of	the	reasons	for	multiple	antidepressants	treatment	in	diabetes	or	could	be	
part	of	the	tailoring	technique	to	suit	the	individual.	
	
Among	individuals	using	oral	anti	glycaemic	agents	only,	the	OR	value	for	single	antidepressant	
usage	is	1.56	(95%	CI	1.52‐1.6),	and	2.0	(95%	CI:	1.9‐2.11)	for	multiple	antidepressants.		
The	 risk	 of	 using	 multiple	 antidepressants	 is	 exceptionally	 large	 compared	 to	 the	 single	
antidepressant.	 Comparing	 these	 two	 show	 that	 the	 OR’s	 can	 be	 considered	 significantly	
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different	 since	 the	 confidence	 intervals	 are	 non‐overlapping	 (Fig.3d).	 This	 indicates	 there	 is	
something	 common	 in	 the	 biochemical	 changes	 in	 diabetes	 and	 depression.	 The	 question	 of	
which	illness	is	the	onset	of	what	then	arises.	
The	main	 issue	 is;	 the	 relationships	between	 these	 two	 illnesses	are	co‐morbid	and	may	need	
further	 research	 to	 designate	 the	 mechanism	 associated.	 Controlling	 type	 2	 diabetes	 is	 a	
challenge.	 	 Individuals	 of	 type	 2	 diabetes	 need	 to	 combine	 changes	 in	 life	 style,	 physical	
activities,	 weight	 regulation	 (especially	 where	 the	 individual	 is	 obese)	 to	 achieve	 effect[195,	
196].	It	is	reasonable	to	assume	that	the	stress	involved	in	controlling	life	style	and	medication	
might	 lead	 to	 depression.	 	 Therefore,	 it	 is	 not	 surprising	 to	 see	 both	 single	 and	 multiple	
antidepressant	usage	as	significant.	As	mentioned	above,	it	is	obvious	that	there	is	a	biochemical	
relationship	between	diabetes	and	depression.	Individuals	that	are	temporarily	depressed	may	
not	need	multiple	antidepressants.	
There	 is	usually	poor	 initial	response	to	antidepressant	medication	 in	 treating	diabetes	 type	2	
due	 to	 multiple	 factors[197].	 This	 could	 also	 be	 another	 reason	 for	 using	 multiple	
antidepressants	or	as	part	of	 the	 tailoring	technique	to	suit	 individuals.	Moreover,	obesity	 is	a	
main	 risk	 factor	 among	 many	 type	 2	 diabetic	 patients	 and	 needs	 attention[198]	 and	 obesity	
being	 a	 risk	 factor	 could	 lead	 to	 depression	 and	 other	 mental	 disorders	 [199].	 It	 will	 be	
appealing	and	challenging	to	do	a	follow	up	on	this	theory	to	see	if	there	is	any	down	regulation	
of	medications.	
	
Among	individuals	using	both	insulin	and	oral	anti	glycaemic	agents,	 the	odds	for	the	usage	of	
single	 antidepressant	 are	 2.0	 (95%	 CI:	 1.90‐2.11).	 The	 odds	 for	multiple	 antidepressants	 are	
2.25	(95%	CI:	2.04‐2.50).	These	values	are	higher	compared	to	the	general	population.		
Individuals	 using	 both	 insulin	 and	 oral	 anti	 glycaemic	 agents	may	 be	more	 related	 to	 type	 2	
diabetes	 since	 insulin	has	proven	 to	be	 successful	 in	 combination	with	oral	 agents,	when	oral	
agents	alone	is	inadequate	or	fades	during	therapy[61,	200].	Although,	some	individuals	of	type	
1	 diabetes	 could	 also	 start	with	 oral	 anti	 glycaemia	 agents	when	necessary[201]	majority	 are	
type	2	 related.	 It	would	be	difficult	 to	categorize	some	 individuals	using	both	 insulin	and	oral	
anti	glycaemic	agents	into	type	1	or	type	2	diabetes.	
Emotional	distress	is	part	of	the	factors	influencing	diabetes	and	depression.	Raising	the	issue	of	
diabetes‐specific	emotional	problems	as	part	of	treating	depressed	diabetic	patients	may	assist	
in	the	management	of	glycaemia	control[202].	Dealing	with	glycaemia	control	and	management	
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might	 help	 combat	 depression	 among	 diabetic	 patients.	 Diabetes	 self‐management	 is	 tedious	
and	 need	 commitment	 of	 time[203],	 which	 could	 be	 one	 of	 the	 causation	 of	 stress[204]	 and	
depression	as	a	co‐morbid	to	the	disease[188].	Diabetic	patients	using	both	insulin	and	oral	anti‐
glycaemia	 agents	 may	 have	 a	 lot	 to	 deal	 with	 the	 issue	 of	 self‐management[203].	 Evidence	
suggests	 depression	 could	 also	 be	 a	 cause	 from	 ineffective	 diabetes	 self‐care[165].	 Although,	
there	are	multiple	of	factors	involved	in	diabetes	self‐	management;	good	self‐care[205]	can	still	
be	 achieved	 through	 interventions	 and	 it	 is	 considered	 as	 an	 important	 part	 of	 clinical	
management	of	diabetes[206].		
It	 is	still	uncertain	why	some	individuals	use	multiple	antidepressants,	while	others	use	only	a	
single	 antidepressant.	 Although	 individuals	 respond	 differently	 to	 medications,	 it	 will	 be	
appropriate	 to	 concentrate	 on	 fewer	 medications	 because	 antidepressants	 treatments	 are	
effective[207]	and	can	be	adjusted	to	suit	individuals.	Therefore,	it	will	be	a	good	idea	to	focus	
on	fewer	antidepressants	(where	patients	are	inactive),	and	concentrate	on	the	management	of	
diabetes.	Moreover,	there	is	evidence	that	long‐term	use	of	antidepressants	can	increase	weight	
gain[208].	 Other	 antidepressants	 could	 increase	 hyperglycemic	 ketoacidosis[209]	 and	 induce	
insulin	resistant[210].		There	are	some	antidepressants	that	could	lower	blood	glucose	level	by	
increasing	insulin	secretion	and		sensitivity[211,	212].	
	
4.3.2 Analysis	 of	 antidepressant	 usage	 among	 diabetic	 individuals	 compared	 to	 the	
general	population	within	age	groups	
The	risk	of	using	single	antidepressant	increases	with	increasing	age	groups	and	declines	from	
age	 group	60‐69	 among	users	 of	 insulin	 only	 (type	1	diabetes).	 The	 risk	was	 also	high	 in	 age	
group	50‐59.	Other	social	 factors	(as	stress)	playing	role	 in	human	 life	could	also	 increase	 the	
risk	of	antidepressants	usage,	because	there	are	higher	levels	of	perceived	stress	and	depressive	
symptoms	in	sensitive	individuals[107].	
The	prevalence	of	using	multiple	antidepressants	was	less	than	single	antidepressants,	although	
not	significantly.	The	risk	of	multiple	antidepressants	usage	decreases	with	increasing	age	group	
until	40‐49.	This	trend	might	be	explained	as;	not	all	individuals	need	multiple	antidepressants	
to	 treat	 depression	 among	 individuals	 using	 insulin	 only	 (diabetes	 type	 1).	However,	 the	 risk	
was	high	among	younger	age	groups	especially	age	group	20‐	29.	Other	studies	have	also	found	
depression	to	be	associated	with	type	1	diabetes[213].	A	Canadian	national	survey	conducted	a	
study	 and	 found	 that	 diabetes	 depression	 is	 strictly	 associated	 with	 age[214].	 Some	 type	 1	
adolescent	diabetes	individuals	are	at	greater	risk	of	mental	problems	in	regard	to	eating,	poor	
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glycaemia	 control	 and	 microvascular	 diabetes	 complications[215].	 The	 complications	 can	
worsen	 from	 late	 adolescent	 life	 and	 affect	 their	 adulthood[215].	 Another	 explanation	 of	 high	
prevalence	 among	 younger	 age	 group	 is	 still	 the	 problem	 of	 obesity.	 The	 trend	 of	 the	 risk	
changes	 again	 at	 age	 group	 50‐59.	 	 Although	 individuals	 in	 these	 age	 groups	 might	 also	 be	
influenced	by	some	factors	as	less	physical	activities,	one	cannot	rule	out	other	chronic	illnesses	
(as	asthma	which	is	not	regarded	during	the	selection	of	individuals	in	this	study).	
There	was	 no	 difference	 in	 the	 risk	when	 comparing	 single	 antidepressant	 usage	 to	multiple	
antidepressants.	These	OR’s	can	be	considered	as	 insignificantly	different	since	 the	confidence	
intervals	are	strongly	overlapping	(Fig.3f).		It	is	questionable	if	patients	using	insulin	only	need	
multiple	antidepressant	treatment	instead	of	focusing	on	diabetes	self‐management.	Although	it	
is	 obvious	 that	 not	 everybody	 might	 be	 able	 to	 cope	 with	 self‐management	 effectively,	 but	
education	is	effective	in	reducing	depression	among	diabetes	patients[216].		
		
Among	patients	using	oral	anti	glycaemic	only	(possibly	diabetes	type	2),	the	prevalence	in	using	
single	 antidepressants	 is	 higher	 than	 the	 general	 population.	 The	 risk	 of	 using	 single	
antidepressants	decreases	with	increasing	age	group	(after	20‐29)	up	to	age	group	50‐59.	There	
were	higher	significant	risks	in	age	groups	20‐29	up	to	50‐59,	and	lower	risks	among	age	groups	
60‐69	and	70‐79.		
In	multiple	antidepressants	usage,	the	prevalence	was	higher	than	the	general	population.	The	
risk	was	also	higher	 in	all	 age	groups	compared	 to	 the	general	population.	The	risk	decreases	
with	increasing	age	group	(after	20‐29)	and	exceptionally	high	in	age	groups	from	30‐39	up	to	
50‐59.		
	
Comparison	of	both	single	and	multiple	antidepressant	usage	indicates	that,	the	risk	was	highly	
significant	 (among	 all	 age	 groups)	 in	 single	 antidepressants	 usage,	 while	 in	 multiple	
antidepressants	 the	 risk	 was	 significant	 in	 some	 age	 groups.	 The	 OR’s	 can	 be	 considered	
significantly	different	 in	the	confidence	 intervals	where	there	 is	no	point	of	overlapping	 in	the	
age	groups.	That	is;	confidence	intervals	of	points	at	age	groups	30‐39,	40‐49	and	50‐49	(Fig.3g).	
There	is	evidence	supporting	the	theory	that,	individuals	40–59	years	of	age	could	be	at	higher	
risk	of	developing	depression	than	any	other	age	group[181],	and	being	diabetic	patient	could	
increase	the	possibility	of	co‐morbidity.	Type	2	diabetes	is	critical	in	all	age	group	and	may	need	
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vigorous	management	and	care.	 	Obesity	is	a	strong	risk	factor	in	both	type	2	diabetes	[3]	and	
depressive	 disorders[217].	 This	 might	 also	 be	 one	 of	 the	 reasons	 for	 seeing	 usage	 of	
antidepressants	in	these	age	groups.	Obesity	in	diabetes	can	be	controlled	with	body	weight	loss	
and	increased	physical	activities.	These	are	some	of	the	important	factors	to	improved	glucose	
tolerance	 and	 insulin	 sensitivity[218].	 	 There	 is	 evidence	 supporting	 previous	 history	 of	
depression	might	 onset	 depression	 among	 diabetes	 individuals	 [219]	 and,	 can	 also	 accelerate	
the	risk	of	diabetes	type	2	compared	to	individuals	without	prior	history		[184].	
	
Among	 individuals	 using	 both	 insulin	 and	 anti	 glycaemic	 agents,	 the	 risk	 decreases	 with	
increasing	age	group	in	the	usage	of	single	antidepressants	(after	age	groups	30‐39).	However,	
the	risk	in	using	single	antidepressant	is	high	among	the	age	group	20‐29;	OR=4.60	(2.71‐7.81)	
and	declines	from	age	groups	60‐69;	OR=1.76	(95%	CI:	 	1.60‐1.93).	The	risk	is	also	low	in	age	
groups	70‐79;	OR=1.54	(95%	CI:	1.39‐1.71).		
In	multiple	 antidepressant	 usage,	 the	 increasing	 risk	 propensity	 starts	 from	 age	 group	 30‐39	
OR=4.60	 (95%	CI:	2.90‐7.29)	and	decreases	with	 increasing	age	group.	There	 is	no	 significant	
risk	 among	 the	 age	 group	 20‐29.	 The	 risks	 among	 age	 groups	 60‐69	 and	 70‐79	 are	marginal	
compared	 to	 other	 age	 groups.	 This	 is	 still	 significantly	 high	 and	 confirms	 the	 findings	 of	 the	
English	 longitudinal	 study	whereby	 diabetes	 is	 also	 associated	with	 depression	 in	 individuals	
over	 50	 years	 of	 age[220].	 The	 study	 predicted	 sociodemographic,	 lifestyle,	 and	 other	 clinical	
factors	being	part	of	the	risk	factors.		
Comparison	of	risks	of	single	and	multiple	antidepressants	indicates	the	OR’s	can	be	considered	
significantly	different	 in	 the	 confidence	 intervals	where	 the	points	are	non‐overlapping	 in	 age	
group	50‐59	(Fig.3h).	One	could	argue	that,	perhaps	the	total	number	of	diabetic	 individual	 in	
age	 groups	 50‐59	 are	 less,	 but	 in	 Fig.3b	 the	 turning	 point	 of	 prescriptions	 of	 antidepressants	
starts	at	age	group	50‐59.	
	The	risks	are	also	significantly	higher	in	individuals	using	both	insulin	and	oral	anti	glycaemic	
agents	 compared	 to	 individuals	 using	 insulin	 only	 (type	 1)	 and	 to	 those	 using	 anti	 glycaemic	
agents	 only	 (types	 2).	 One	 explanation	 could	 be	 that,	 even	 though	 the	 use	 of	 insulin	 and	 oral	
anti‐glycaemia	 agents	 betters	 the	 situation	 or	 help	manage	 the	 illness,	 there	 could	 be	 tedious	
work	 involved.	 Secondly,	 in	 the	 long	 run,	managing	 the	disease	 could	be	 emotional	 and	 could	
involve	depression[167].		
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As	stated	above,	individuals	using	both	insulin	and	anti	glycaemic	agents	are	possibly	related	to	
type	2	diabetes.	Diabetes	depression	is	also	found	to	be	associated	with	poor	glycaemia	control	
in	both	types	1	and	2	diabetes	[167,	221].	Evidence	suggests	depression	among	diabetes	could	
be	 associated	 with	 poor	 diet	 and	 or	 poor	 metabolic	 control[183],	 and	 non‐adherence	 to	
medication[222].	The	disease	burden	can	be	reduced	with	adherence	to	better	medication[59].	
As	 found	 in	 a	meta‐analysis,	 depression	 itself	may	 be	 a	 risk	 factor	 for	 noncompliance	 among	
patients	with	medical	treatment[223],	and	being	a	diabetic	patient	and	noncompliance	could	be	
a	significant	risk	factor	for	depression.	
Other	hypotheses	states	the	interactions	between	biological	and	psychosocial	factors	are	what	is	
causing	 depression	 in	 diabetes	 individuals.	 This	 interaction	 could	 cause	 diabetes	 in	 healthy	
individuals.	
	
4.3.3 Gender	analysis	
Gender	plays	a	role	in	the	prevalence	of	diabetes	in	general.	The	prevalence	of	diabetes	is	higher	
among	men	 than	women,	 even	 though	 there	 are	more	women	with	 the	 disease	 than	men[3].	
Depression	is	also	related	to	gender	among	diabetes[161]	and	to	general	depression.	
Among	 individuals	 using	 insulin	 only	 (type	 1	 diabetes),	 the	 risk	 for	 males	 in	 using	 single	
antidepressants	 was	 1.61.	 The	 risk	 for	 females	 was	 only	 slightly	 lower	 (1.52).	 In	 multiple	
antidepressants,	males	had	1.70	whiles	females	had	an	OR	of	1.39.	There	was	no	significant	or	
marginable	difference	in	risks	among	gender	when	it	comes	to	single	antidepressant	usage,	but	
there	was	a	substantial	difference	in	multiple	antidepressants	usage.		
Among	 individuals	 using	 oral	 anti	 glycaemic	 only	 (type	 2	 diabetes),	 the	 risk	 for	 men	 was	
OR=1.56	and	females;	OR=1.58.	In	multiple	antidepressants,	males	had	OR=1.86.	Whiles	females	
had	OR	of	1.86.	Here	there	was	no	significant	difference	in	gender	in	respect	to	antidepressant	
usage	in	general.	
For	 individuals	 using	 both	 insulin	 and	 oral	 anti	 glycaemic	 agents,	 the	 risk	 of	 using	 single	
antidepressants	 among	 males	 was	 OR=2.06	 and	 for	 females	 OR=1.98.	 The	 risk	 of	 multiple	
antidepressants	usage	for	males	was	OR=2.33	and	for	females	OR=	2.23.	As	the	values	speak	for	
themselves,	the	differences	in	risk	values	were	remarkably	little.	
As	 seen	 above,	 the	 difference	 in	 risks	 among	men	 and	women	was	 substantial	 in	 individuals	
using	 insulin	 only	 (type	 1	 diabetes).	 There	 were	 no	 significant	 differences	 in	 gender	 among	
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individuals	using	oral	anti	glycaemic	only	(types	2)	and	in	individuals	using	both	insulin	and	oral	
anti	glycaemic	agents.	Depression	 is	also	associated	with	obesity	among	women[224],	but	 this	
tendency	seems	to	be	less	influential	in	these	findings,	although	obesity	was	not	measured.	
	
	
4.3.4 	Relationship	between	diabetes	and	depression	
The	 co‐morbidity	 of	 diabetes	 and	 depression	 was	 long	 identified	 by	 a	 British	 scientist	 many	
years	 ago[216].	 The	 prevalence	 of	 diabetes	 is	 increasing	 and	 likewise	 the	 prevalence	 of	
depression	among	diabetic	patients[7,	225].	Both	minor	and	major	depression	in	diabetes	is	also	
related	 to	mortality[226].	 There	 are	 several	 publications	 regarding	 the	 relationships	 between	
diabetes	and	depression.	Some	predict	and	theorizes	diabetes	to	be	the	risk	factor	of	depression,	
and	 others	 predict	 or	 hypothesize	 the	 opposite.	 	 The	 findings	 in	 this	 study	 support	 and	
strengthen	the	theories	that	there	is	a	significant	correlation	between	diabetes	and	depression,	
but	cannot	predict	the	bi‐direction	of	co‐morbidity	of	the	two	illnesses.	
	
4.3.5 Depression	as	a	risk	factor	for	diabetes	
As	stated	earlier,	several	studies	have	provided	substantial	evidence	and	theories	regarding	the	
relationship	 of	 diabetes	 and	depression,	where	depression	was	 also	 predicted	 as	 the	 onset	 of	
diabetes	and	vice	versa.		Knol	et	al	hypothesized	in	a	meta‐analysis	that	depression	is	an	onset	of	
diabetes	where	they	 found	37	%	risk	of	developing	diabetes	 type	2	among	depressed	patients	
(compared	to	other	risk	factors)[164],	even	though	they	couldn’t	deduct	the	pathophysiological	
mechanisms	underlying	 the	 relationships	between	 the	 illnesses.	 A	 similar	 study	 conducted	by	
Eaton	et	al,	also	indicated	diabetes	to	be	an	onset	of	depression[227].	
In	a	follow	up	study	of	8	years	(conducted	in	Japan	among	depressed	individuals	n= 2,380),	41	
incidences	appeared	to	have	developed	type	2	diabetes.	The	study	concluded	depression	was	a	
risk	 factor	 for	developing	diabetes	 [228].	Assuming	these	 individuals	received	antidepressants	
for	 treatment	 (during	 the	 follow‐up)	 could	 also	 have	 influenced	 the	 outcome.	 Some	
antidepressants	 have	 the	 tendency	 to	 increase	 the	 risk	 of	 hyperglycemia	 or	 interfere	 with	
glucose	homeostasis	(especially	olanzapine,	sertraline	and	some	Tricyclic	and	SSRIs)[208,	209,	
211].	 Secondly,	 some	 antidepressants	 reduce	 insulin	 sensitivity[229]	 and	 or	 disturbs	 the	
homeostasis	of	glucose[230].	Therefore	antidepressants	should	be	assessed	with	care.	
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In	a	longitudinal	study,	older	adults	were	also	found	to	be	at	higher	risk	in	developing	diabetes	
type	2	as	a	result	of	depression[231].	Others	have	also	evidenced	that	increased	risk	of	diabetes	
in	younger	adults	is	a	result	of	depression[184],	This	literature	is	somehow	questionable,	even	
though	it	sounds	logic	since	type	2	diabetes	is	usually	associated	with	downregulation	of	insulin	
sensitivity	in	older	individuals.	
Several	studies	have	predicted	depression	to	increase	the	risk	of	diabetes	through	mechanisms	
that	 include	 psychosocial	 and	 behavioral	 factors.	 Factors	 such	 as	 physical	 inactivity,	 elevated	
BMI,	smoking,	obesity	and	sleep	disorders	and	physiological	or	hormonal	factors	(such	as	stress)	
could	 all	 be	 associated	 with	 depression[185,	 232].	 Depressed	 individuals	 may	 have	 all	 these	
characteristics	 and	 might	 affect	 their	 lifestyle.	 Blood	 sugar	 itself	 being	 a	 potent	 of	 mood	
regulator	can	have	effect	on	diabetes	and	depression.	
Stress	can	initiate	the	release	of	neurotransmitters,	growth	hormone,	glucagon,	and	impairment	
of	hypothalamic–pituitary–adrenal	(HPA)	controlling	cortisol	(which	can	elevate	blood	glucose	
levels)	 and	 could	 lead	 to	 diabetes	 type	 2	 symptoms[216].	 Depression	 in	 diabetes	 is	 also	
associated	 with	 or	 it	 is	 due	 to	 hyper‐secretion	 or	 elevated	 levels	 of	 IL‐6,	 TNF‐α,	 and	 other	
cytokines[232].	 	 These	 pro‐inflammatory	 cytokines	 are	 also	 risking	 factors	 for	 diabetes	 and	
could	interfere	with	insulin	action.	
4.3.6 Diabetes as a risk factor for depression 
Diabetes	as	a	risk	predictor	of	depression	is	also	known,	and	there	are	several	publications	on	
this	 issue.	 	 As	 stated	 earlier	Anderson	 et	 al.	 concluded	 in	 a	meta‐analysis	 as	 diabetic	 patients	
having	double	the	risk	of	becoming	depressed	compared	to	non‐diabetes[182].	
In	another	research	(where	drug	use	was	used	in	the	methodology	as	in	this	thesis),	they	found	
no	linkage	of	depression	being	the	cause	of	diabetes,	but	rather	the	use	of	diabetes	medication	
being	a	risk	factor	of	depression	[192].		
In	a	review	by	Talbot	et	al,	they	hypothesized	that	early	clinical	depression	and	major	depressive	
disorders	propagates	from	biochemical	changes	of	type	2	diabetes	[233].	However,	they	did	not	
eliminate	 the	burden	of	 treatment	and	 the	disease	 itself	as	being	risk	 factors.	The	burden	and	
psychological	 distress	 can	 also	 be	 explained	 with	 the	 findings	 of	 other	 studies,	 where	 they	
confirmed	 diabetes‐specific	 emotional	 distress	 as	 being	 predictors	 of	 depression	 [202,	 234].	
Other	studies	have	also	hypothesized	that	psychosocial	factors	are	key	predictors	in	the	diabetes	
care	(in	both	children	and	adults)[235].	Psychosocial	factors	and	diabetes	care	can	be	improved	
through	 regimen	 or	 medication	 adherence	 [222,	 223,	 236]	 and	 glycemic	 control[167,	 207].	
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Psychosocial	functioning	could	also	be	achieved	through	self‐	management	[166,	206,	237,	238].	
All	 these	 factors	 together	 could	 improve	 the	quality	 of	 life	 [186,	 239,	 240].	Obesity	 cannot	be	
ruled	 out	 as	 a	 factor	 having	 an	 impact	 on	 the	 quality	 of	 life	 among	 diabetes	 individuals	
[241].There	is	evidence	confirming	depression	in	diabetes	results	from	diabetes		complications	
including	micro	and	macro‐vascular	diseases	[242,	243].	
4.3.7 Other	hypotheses	(	astroglial	hypothesis)	
Although	some	studies	found	no	association	between	diabetes	and	glycaemia	control[190,	191,	
244],	 there	 is	 meta‐analysis	 review	 that	 found	 depression	 and	 diabetes	 to	 occur	 in	 both	
direction[166].	Whether	diabetes	is	the	onset	of	depression	or	vice	versa,	the	main	goal	is	to	use	
appropriate	channels	of	treatment	to	improve	the	quality	life	of	diabetic	patients.	
Hundals	astroglial	hypothesis	proposed	in	2007	helps	to	strengthen	the	research	of	diabetes	and	
depression.	 The	 hypothesis	 briefs	 the	 axis	 of	 depression	 should	 be	 perceived	 as	 a	 result	 of	
dysfunctional	astroglial	bioenergetics,	a	cerebral	hypoglycometabolic	syndrome.	Depression	is	a	
diverse	disease	and	should	not	be	viewed	as	a	specific	biochemical	disorder.	Depression	should	
be	 viewed	 from	 a	 clinical	 angle	 as	 a	 broad	 pathological	 disorders	 rooting	 from	 a	 common	
denominator,	in	other	words;	an	“impaired	cerebral	glucose	metabolism”[245].	
In	a	major	depressive	disorder,	the	concept	may	be	explained	as	interference,	down	regulation,	
or	failure	in	the	glucose	metabolism	of	the	astroglia.	In	mild	to	moderate	depressive	disorders,	
the	 system	 (glucose	 metabolism)	 is	 less	 affected,	 and	 if	 not	 none,	 includes	 the	 ability	 and	
function	 of	 the	 neurons.	 Glucose	 transporters	 are	 present	 in	 the	 blood	 brain	 barrier	 (in	
astroglia).  The	 target	 of	 insulin	 secretion	 in	 the	 brain	 is	 the	 astroglial	 and	 not	 the	 neurons.	
Depressed	 individuals	 may	 have	 downregulation	 in	 glial	 cells	 which	 explains	 glucose	
metabolism	in	the	astroglial	may	play	an	important	role	in	depression.	
	
4.3.8 Implications	of	the	study	
The	study	may	have	implications	on	the	following	two	important	areas.		
4.3.9 Clinical	practice	and	perceived	health	
Diabetes	is	a	chronic	disease	rated	as	one	of	the	disease	that	can	hamper	human	life.		Hopefully	
the	thesis	has	raised	awareness	with	regard	to	the	treatment	of	depression	in	diabetes	and	the	
usage	 of	 antidepressants.	 Clinicians	 can	 have	 a	 picture	 of	 the	 trend	 of	 prescriptions	 of	
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antidepressant	 to	 diabetic	 patients.	 Secondly	 clinicians	 can	 consider	 when	 to	 use	 single	 or	
multiple	antidepressants	usage.	Thus,	 antidepressants	 that	 can	cause	weight	gain	and	or	have	
the	potential	risks	of	causing	irregularities	on	glycaemia	should	be	reassessed.	
Both	 health	 personnel	 and	 patients	 may	 work	 together	 to	 improve	 diabetic	 patients	 health	
through	 interventions[246]	 that	 might	 also	 have	 a	 greater	 impact	 on	 perceived	 heath	 of	
individuals.	Perceived	health	measures	subjective	health	of	individuals.	It	deals	with	the	general	
health	 of	 the	 individual	 (and	 includes	 all	 factors	 that	 affects	 the	 health)[247].	 In	Norway,	 the	
perceived	health	of	the	general	population	is	exceptionally	good	(8	out	of	10)[248].	Likewise,	the	
perceived	health	among	the	general	population	in	Europe	is	also	good	[247].	
	
4.3.10 	Future	studies	
This	 thesis	 has	 drawn	 a	 variety	 of	 attention	 on	 the	 use	 of	 antidepressants.	 There	 are	 several	
researches	on	the	linkage	between	diabetes	and	depression.	The	findings	in	this	thesis	have	also	
strengthened	 the	 result	 of	 other	 studies	 with	 a	 significant	 association	 between	 diabetes	 and	
depression.	There	is	still	in	need	of	research	to	resolve	the	bidirectional	development	of	diabetes	
and	 depression	 especially	 the	mechanistic	 direction	 of	 the	 co‐morbidity.	 A	 follow	 up	 study	 is	
strongly	 recommended	 in	 this	 cross	 sectional	 epidemiological	 area	 of	 research.	 	 Lastly	 and	
probably	more	confoundable	factors	(as	chronic	illnesses)	could	be	taken	into	account	in	future	
studies.
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5. Conclusion	
This	 thesis	 studied	 the	 usage	 of	 single	 and	 multiple	 antidepressants	 among	 patients	 with	
diabetes.		The	findings	in	this	thesis	indicate	that,	the	use	of	single	antidepressants	is	higher	than	
the	use	of	multiple	antidepressants	among	diabetic	individuals	as	it	is	in	the	general	population.	
There	was	a	 significant	 risk	of	using	both	 single	 and	multiple	 antidepressants	 among	diabetic	
individuals	compared	to	non‐diabetes	in	the	general	population.			
In	the	overall	 findings	and	compared	to	the	general	population,	 there	was	no	difference	 in	the	
risk	of	using	single	and	multiple	antidepressants	within	patients	using	 insulin	only.	There	was	
also	 a	 substantial	 risk	 of	 using	 single	 antidepressants	 among	 patients	 using	 oral	 anti	 diabetic	
agents	 only	 compared	 to	 the	 general	 population	 and	 highly	 significant	 risk	 of	 using	 multiple	
antidepressants	compared	to	the	general	population.	The	difference	was	significant,	 i.e.	among	
these	patients	 there	was	 a	higher	use	of	multiple	 antidepressants	 than	 single	 antidepressants	
compared	 to	 the	 general	 population.	 Patients	 using	 both	 insulin	 and	 oral	 antidiabetic	 agents	
have	 double	 risk	 of	 using	 both	 single	 and	multiple	 antidepressants	 compared	 to	 the	 general	
population.		
The	reason	for	why	patients	using	oral	anti	glycaemic	agents	more	often	are	prescribed	multiple	
antidepressants	compared	to	the	general	population	is	unknown.		
Among	the	age	groups,	there	is	substantial	risk	of	using	both	single	and	multiple	antidepressants	
among	patients	using	insulin	only	compared	to	the	general	population.	The	risk	of	using	single	
antidepressants	increases	with	increasing	age	group,	and	declines	from	age	group	60	upwards.	
The	risk	of	multiple	antidepressant	usage	also	decreases	with	age.	 	Among	patients	using	oral	
antidiabetic	 only,	 the	 risks	 of	 using	 both	 single	 and	 multiple	 antidepressants	 decreases	 with	
increasing	age	group.	However	the	risk	is	higher	among	younger	adults	compared	to	the	general	
population	and	lower	among	individuals	from	60	years	and	above.		The	risk	of	using	both	single	
and	 multiple	 antidepressants	 is	 also	 higher	 among	 young	 adults	 using	 both	 insulin	 and	 oral	
antidiabetic	agents	and,	decreases	with	increasing	age	group.	
The	risks	of	using	multiple	versus	single	antidepressants	were	similar	between	men	and	women.	
Although	 the	 prevalence	 is	 higher	 in	 women	 than	 men,	 there	 is	 a	 negligible	 risk	 of	 using	
antidepressants	among	men	than	women.																																		
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Finally	 the	 findings	 confirm	 the	 relationship	 between	 diabetes	 and	 depression	 shown	 in	
previous	studies,	but	these	results	cannot	be	used	to	judge	whether	diabetes	increases	the	risk	
of	depression	or	vice	versa.	Further	 research	 is	 strongly	 recommended,	especially	a	 follow	up	
study	 that	 might	 help	 explore	 the	 relationship,	 the	 nature	 and	 the	mechanisms	 of	 these	 two	
global	burdens	of	illnesses.	
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